Document History Section 3.2 Study Duration • Added clinic visits on Day 225 (Month 8), Day 253 (Month 9), Day 281 (Month 10), Day 309 (Month 11), Day 337 (Month 12), and Day 365 (Month 13). • Revised maximum study duration to 15 months (365 days for subjects continuing from study B7841002). Section 4.1 Inclusion Criterion • Revised Inclusion Criterion #2 for de novo subjects to add the requirement for episodic (on-demand) treatment prior to screening, as mandated by the FDA. • Added Inclusion Criterion #3 for de novo subjects to add the requirement for 6 or more breakthrough bleeding episodes in the 6 month period prior to screening, as mandated by the FDA. Section 5.2 Subject Compliance • Revised visit day numbers to correspond to up to 365 days treatment duration. Section 5.3.2 Preparation and Dispensing • Revised visit day numbers to correspond to up to 365 days treatment duration. Section 6.2.3 Day 29 [±±2 days], Day 57 [±5 days], Day 85 [±5 days], Day 113 [±7 days], Day 141 [±7 days], Day 169 [±7 days], Day 225 [±7 days], Day 253 [±7 days], Day 281 [±7 days], Day 309 [±7 days], Day 337 [±7 days], and Day 365 [±7 days] Visits • Revised section to add clinic visits on Day 225, Day 253, Day 281, Day 309, Day 337, and Day 365. s u bj e ct s o nl y.  C CI  R e vi s e d vi sit d a y n u m b er s t o c orr e s p o n d t o u p t o 3 6 5 d a y s tr e at m e nt d ur ati o n. S e cti o n 6. 2. 4 D a y 3 9 3 [  7 d a y s] – E n d of St u d y Vi sit  R e vi s e d s e cti o n t o a d d cli ni c vi sit o n D a y 3 9 3.  R e vi s e d vi sit d a y n u m b er s t o c orr e s p o n d t o u p t o 3 6 5 d a y s tr e at m e nt d ur atio n. S e cti o n 7. 8 Bl o o d V ol u m e  R e vi s e d T a bl e 4 t o i n cl u d e a d diti o n al s a m pl e s. A m e n d m e nt 1 1 1 J u n e 2 0 1 8 Titl e  R e m o v e d “ or I ntr a v e n o u s ” a s t hi s r o ut e of a d mi ni str ati o n will n ot b e u s e d i n t hi s st u d y . G e n e r al C h a n g e s T h r o u g h o ut P r ot o c ol  E dit ori al c h a n g e s t o fi x titl e s, h e a d er s, gr a m m ar a n d t y p o gr a p hi c al err or s. P r ot o c ol S u m m a r y  I ncl u d e d s u bj e ct s wit h i n hi bit or s t o F VIII or FI X.  I ncl u si o n of a d ol e s c e nt s u bj e ct s  1 2 t o < 1 8 y e ar s of a g e. S c h e d ul e of A cti viti e s  S cr e e ni n g: • Added assent/parental consent. • Added CD4 cell count lab. • Added Factor VIII or Factor IX inhibitor labs. Added footnote ‘o’ for instructions on inhibitor labs. • Added cardiac troponin I labs for de novo subjects from Day 1 to Day 29. • Updated footnote ‘m’ to add guidance on interim visits to perform IP administration or monitor self-administration. Section 1.1 Mechanism of Action/Indication • Included subjects with inhibitors to FVIII or FIX. Section 1.2.3 Clinical Experience with PF-06741086 • Included subjects with inhibitors to FVIII or FIX. • Added text to indicate that interim clinical data from B7841002 may be found in the PF-06741086 Investigator’s Brochure. Section 1.2.5 Dose Rationale • Added text to clarify dose assignments based on results from study B7841002. Section 1.2.6 Summary of Risk/Benefit • Included subjects with inhibitors to FVIII or FIX. Section 2 Study Objectives and Endpoints • Included subjects with inhibitors to FVIII or FIX. Section 3 Study Design • Included subjects with inhibitors to FVIII or FIX. • Figure 1 was updated to clarify dose assignments based on results from study B7841002. Section 3.2 Study Duration • Editorial changes and clarifying text added regarding visit windows, visit requirements, and the use of unscheduled visits. Section 4.1 Inclusion Criteria • Included subjects with inhibitors to FVIII or FIX. • Inclusion of adolescent subjects ≥12 to <18 years of age. • Removal of requirements for episodic treatment and 6 or more breakthrough bleeds prior to study entry. Section 4.2 Exclusion Criteria • Included subjects with inhibitors to FVIII or FIX. • An exclusion criterion regarding known severe hypercholesterolemia was added to comply with competent authority/ethics committee requests in France and Switzerland. Section 4.3 Randomization Criteria • Included subjects with inhibitors to FVIII or FIX. Section 5 Study Treatments • Removal of 100 mg/mL concentration from the study. Section 5.3.1 Dosage Form(s) and Packaging • Removal of 100 mg/mL concentration from the study. Section 5.4 Administration • Editorial changes to clarify SC administrations. Section 5.7.1 Prohibited Medications • Included subjects with inhibitors to FVIII or FIX. • Restrictions on rFVIIa dose level and prohibition of FEIBA conforms to study B7841002. Section 5.7.2 Treatment(s) for Acute Bleeding Episodes • Included subjects with inhibitors to FVIII or FIX. Section 6.1 Screening • Included subjects with inhibitors to FVIII or FIX. • Inclusion of adolescent subjects ≥12 to ≤18 years of age. • Added assent/parental consent. • Added CD4 cell count. • Added Factor VIII or Factor IX inhibitor labs (for subjects with hemophilia. Section 6.2.1 Day 1 Visit • Included subjects with inhibitors to FVIII or FIX. Section 7.1.1 Laboratory Tests  IFIncXl.u d e d s u bj e ct s wit h i n hi bit or s t o F VIII or  E dit ori al c h a n g e t o a d d C D 4 c ell c o u nt t o t a bl e. S e cti o n 7. 1. 3 Bl o o d P r e s s u r e a n d P ul s e R at e s  E dit ori al c h a n g e t o r e m o v e t h e t er m “i ntr a v e n o u s ” w hi c h w a s n ot p art of t h e fi n al st u d y d e si g n. S e cti o n 7. 2. 5 Bl o o d P r e s s u r e a n d P ul s e R at e s  I ncl u si o n of s u bj e ct s wit h i n hi bit or s t o F VIII or FI X. C CI S e cti o n 7. 8 Bl o o d V ol u m e  U p d at e d m a xi m u m t ot al bl o o d v ol u m e i n T a bl e 4. S e cti o n 9 D at a A n al y si s/ St ati sti c al M et h o d s  E dit ori al c h a n g es r e g ar di n g st atisti c al h y p ot h esis t esti n g a n d s af et y a n al ysis. Ori gi n al V er si o n 1 7 A pril 2 0 1 7 N/ A T hi s a m e n d m e nt i n c or p or at e s all r e vi si o n s t o d at e, i n cl u di n g a m e n d m e nt s m a d e at t h e r e q u e st of c o u ntr y h e alt h a ut h oriti e s a n d i n stit uti o n al r e vi e w b o ar d s (IR B s)/ et hi c s c o m mitt e e s (E C s). TABLE OF CONTENTS LIST OF TABLES ...................................................................................................................13 LIST OF FIGURES .................................................................................................................13 APPENDICES .........................................................................................................................13 PROTOCOL SUMMARY.......................................................................................................14 SCHEDULE OF ACTIVITIES................................................................................................16 1. INTRODUCTION ...............................................................................................................22 1.1. Mechanism of Action/Indication.............................................................................22 1.2. Background and Rationale ......................................................................................22 1.2.1. Nonclinical Pharmacology and Pharmacokinetics .....................................23 1.2.2. Nonclinical Toxicology ..............................................................................24 1.2.3. Clinical Experience with PF-06741086......................................................25 1.2.4. B7841003 Study Rationale .........................................................................26 1.2.5. Dose Rationale............................................................................................26 1.2.6. Summary of Risk/Benefit ...........................................................................26 2. STUDY OBJECTIVES AND ENDPOINTS.......................................................................28 3. STUDY DESIGN.................................................................................................................29 3.1. Planned Number of Subjects ...................................................................................30 3.2. Study Duration ........................................................................................................30 3.3. Dose Modification Rules for Adverse Events .........................................................31 3.3.1. Dose Modification Rules for Breakthrough Bleeding Episodes.................31 4. SUBJECT ELIGIBILITY CRITERIA.................................................................................32 4.1. Inclusion Criteria.....................................................................................................32 4.2. Exclusion Criteria....................................................................................................33 4.3. Randomization Criteria ...........................................................................................34 4.4. Lifestyle Requirements ...........................................................................................35 4.4.1. Contraception..............................................................................................35 4.5. Sponsor’s Qualified Medical Personnel ..................................................................36 5. STUDY TREATMENTS.....................................................................................................36 5.1. Allocation to Treatment ..........................................................................................37 5.2. Subject Compliance.................................................................................................37 5. 3. 2. Pr e p ar ati o n a n d Di s p e n si n g ........................................................................ 3 8 5. 4. A d mi ni str ati o n ......................................................................................................... 3 8 5. 5. I n v e sti g ati o n al Pr o d u ct St or a g e .............................................................................. 3 9 5. 6. I n v e sti g ati o n al Pr o d u ct A c c o u nt a bilit y ................................................................... 3 9 5. 6. 1. D e str u cti o n of I n v e sti g ati o n al Pr o d u ct S u p pli e s ........................................ 4 0 5. 7. C o n c o mit a nt Tr e at m e nt( s) ....................................................................................... 4 0 5. 7. 1. Pr o hi bit e d M e di c ati o n s ............................................................................... 4 0 5. 7. 2. Tr e at m e nt( s) f or A c ut e Bl e e di n g E pi s o d e s ................................................. 4 1 6. S T U D Y P R O C E D U R E S ..................................................................................................... 4 1 6. 1. S cr e e ni n g ................................................................................................................. 4 1 6. 2. St u d y P eri o d ............................................................................................................ 4 4 6. 2 . 1. D a y 1 Vi sit [ + 1 d a y] ...................................................................................4 4 6. 2. 2. D a y 2 [ 1 d a y ], D a y 4 [ 1 d a y ], D a y 8 [ 2 d a y s], D a y 1 5 [ 2 d a y s], D a y 2 2 [  2 d a y s] a n d D a y 2 9 [ 2 d a y s] – C CI a n d Tr e at m e nt Vi sit s f or D e N o v o S u bj e ct s ....................................................................................... 4 6 6. 2. 3. D a y 2 9 [ 2 d a y s], D a y 5 7 [ 5 d a y s], D a y 8 5 [ 5 d a y s], D a y 1 1 3 [  7 d a y s], D a y 1 4 1 [  7 d a y s], D a y 1 6 9 [ 7 d a y s], D a y 2 2 5 [ 7 d a y s], D a y 2 5 3 [ 7 d a y s], D a y 2 8 1 [  7 d a y s], D a y 3 0 9 [  7 d a y s ], D a y 3 3 7 [  7 d a y s], a n d D a y 3 6 5 [ 7 d a y s] Vi sit s .................................................. 4 7 6. 2. 4. D a y 3 9 3 [ 7 d a y s] – E n d of St u d y Vi sit..................................................... 4 9 6. 2. 5. F oll o w -u p C o nt a ct ...................................................................................... 4 9 6. 3. S u bj e ct Wit h dr a w al or E arl y T er mi n ati o n ..............................................................4 9 7. A S S E S S M E N T S .................................................................................................................. 5 1 7. 1. S af et y ....................................................................................................................... 5 1 7. 1. 1. L a b or at or y T e st s ......................................................................................... 5 1 7. 1. 2. P h y si c al E x a mi n ati o n s ................................................................................ 5 3 7. 1. 3. Bl o o d Pr e s s ur e a n d P ul s e R at e ...................................................................5 3 7. 1. 4. R e s pir at or y R at e .........................................................................................5 3 7. 1. 5. T e m p er at ur e ................................................................................................ 5 3 7. 1. 6. El e ctr o c ar di o gr a m ....................................................................................... 5 3 7. 1. 7. I nj e cti o n Sit e R e a cti o n s ..............................................................................5 4 7. 2. Effi c a c y ................................................................................................................... 5 5 7. 2. 2. Bl e e di n g ...................................................................................................... 5 5 7. 2. 3. T y p e s o f Bl e e di n g ....................................................................................... 5 5 7. 2. 4. L o c ati o n of Bl e e d s ...................................................................................... 5 6 7. 2. 5. Tr e at m e nt of Bl e e di n g E pi s o d e s ................................................................. 5 6 C CI ............................................................................................ 5 7 C CI ......................................................... 5 7 C CI ...................................................... 5 7 C CI ...................................................................................................... 5 7 C CI .......................................................................... 5 7 C CI ..................... 5 8 C CI ....................................................... 5 8 C CI .................................................................................................. 5 8 C CI ........................................................................ 5 8 C CI ............................................................ 5 8 C CI ............................................ 5 8 C CI ............................. 5 9 C CI ................................................... 5 9 C CI ............................................................................... 5 9 C CI .............................................................................. 5 9 C CI ............................................................................................. 5 9 C CI .................................................................................... 6 0 7. 8. Bl o o d V ol u m e ......................................................................................................... 6 0 8. A D V E R S E E V E N T R E P O R TI N G ...................................................................................... 6 2 8. 1. R e q uir e m e nt s ........................................................................................................... 6 2 8. 1. 1. A d diti o n al D et ail s O n R e c or di n g A d v er s e E v e nt s o n t h e C R F ..................6 3 8. 1. 2. Eli citi n g A d v er s e E v e nt I nf or m ati o n .......................................................... 6 4 8. 1. 3. Wit h dr a w al Fr o m t h e St u d y D u e to A d v er s e E v e nt s ( s e e al s o t h e S u bj e ct Wit h dr a w al or E arl y T er mi n ati o n s e cti o n) ......................................... 6 4 8. 1. 4. Ti m e P eri o d f or C oll e cti n g A E/ S A E I nf or m ati o n ...................................... 6 4 8. 1. 4. 1. R e p orti n g S A E s t o Pfi z er S af et y ............................................... 6 4 8. 1. 4. 2. R e c or di n g N o n -s eri o u s A E s a n d S A E s o n t h e C R F ................. 6 4 8. 1. 6. S p o n s or’ s R e p orti n g R e q uir e m e nt s t o R e g ul at or y A ut h oriti e s .................. 6 5 8. 2. D efi niti o n s ............................................................................................................... 6 5 8. 2. 1. A d v er s e E v e nt s ........................................................................................... 6 5 8. 2. 2. A b n or m al T e st Fi n di n g s ............................................................................. 6 6 8. 2. 3. H e m o p hili a E v e nt s ...................................................................................... 6 6 8. 2. 4. S eri o u s A d v er s e E v e nt s .............................................................................. 6 7 8. 2. 5. H o s pit ali z ati o n ............................................................................................ 6 8 8. 3. S e v erit y A s s e s s m e nt................................................................................................ 6 9 8. 4. S p e ci al Sit u ati o n s .................................................................................................... 6 9 8. 4. 1. Pr ot o c ol - S p e cifi e d S eri o u s A d v er s e E v e nt s ............................................... 6 9 8. 4. 2. P ot e nti al C a s e s of Dr u g -I n d u c e d Li v er I nj ur y............................................ 7 0 8. 4. 3. E x p o s ur e t o t h e I n v e sti g ati o n al Pr o d u ct D uri n g Pr e g n a n c y or Br e a stf e e di n g, a n d O c c u p ati o n al E x p o s ur e .....................................................7 1 8. 4. 3. 1. E x p o s ur e D uri n g Pr e g n a n c y ...................................................... 7 1 8. 4. 3. 2. E x p o s ur e D uri n g Br e a stf e e di n g ................................................ 7 3 8. 4. 3. 3. O c c u p ati o n al E x p o s ur e ............................................................. 7 3 8. 4. 4. M e di c ati o n Err or s ....................................................................................... 7 3 8. 4. 4. 1. M e di c ati o n Err or s ...................................................................... 7 3 8. 5. M e di c al D e vi c e C o m pl ai nt R e p orti n g R e q uir e m e nt s ............................................. 7 4 9. D A T A A N A L Y SI S/ S T A TI S TI C A L M E T H O D S...............................................................7 4 9. 1. S a m pl e Si z e D et er mi n ati o n ..................................................................................... 7 4 9. 2. Effi c a c y A n alys i s .................................................................................................... 7 5 9. 2. 1. A n al y si s of t h e Effi c a c y E n d p oi nt..............................................................7 5 C CI .................................................................7 5 C CI ...............................................................7 5 C CI ................................................................................... 7 5 9. 6. S af et y A n al ys i s........................................................................................................ 7 5 9. 7. I nt eri m A n al ys i s ...................................................................................................... 7 6 9. 8. D at a M o nit ori n g C o m mitt e e ................................................................................... 7 6 1 0. Q U A LI T Y C O N T R O L A N D Q U A LI T Y A S S U R A N C E .................................................7 6 1 1. D A T A H A N D LI N G A N D R E C O R D K E E PI N G ............................................................. 7 7 1 1. 2. R e c or d R et e nti o n ................................................................................................... 7 7 1 2. E T HI C S ..............................................................................................................................7 8 1 2. 1. I n stit uti o n al R e vi e w B o ar d/ Et hi c s C o m mitt e e ...................................................... 7 8 1 2. 2. Et hi c al C o n d u ct of t h e St u d y ................................................................................ 7 8 1 2. 3. S u bj e ct I nf or m ati o n a n d C o n s e nt .......................................................................... 7 8 1 2. 4. R e p orti n g of S af et y I s s u e s a n d S eri o u s Br e a c h e s of t h e Pr ot o c ol or I C H G C P ........................................................................................................................... 7 9 1 3. D E FI NI TI O N O F E N D O F T RI A L ................................................................................... 8 0 1 3. 1. E n d of Tri al i n a M e m b er St at e ............................................................................. 8 0 1 3. 2. E n d of Tri al i n All Ot h er P arti ci p ati n g C o u ntri e s ................................................. 8 0 1 4. S P O N S O R DI S C O N TI N U A TI O N C RI T E RI A ................................................................ 8 0 1 5. P U B LI C A TI O N O F S T U D Y R E S U L T S .......................................................................... 8 0 1 5. 1. C o m m u ni c ati o n of R e s ult s b y Pfi z er .................................................................... 8 0 1 5. 2. P u bli c ati o n s b y In v e sti g at or s ................................................................................ 8 1 1 6. R E F E R E N C E S .................................................................................................................. 8 3 L I S T O F T A B L E S T a bl e 1. S cr e e ni n g, D a y 1 t o D a y 3 9 3, All S u bj e ct s .......................................................... 1 6 T a bl e 2. D a y 2 t hr o u g h D a y 2 2: C CI a n d Tr e at m e nt Vi sit s f or D e N o v o S u bj e ct s....... 2 1 T a bl e 3. L a b or at or y T e st s ................................................................................................... 5 2 T a bl e 4. Bl o o d V ol u m e ....................................................................................................... 6 1 T a bl e 5. Tri g g er e d R e q uir e m e nt s ....................................................................................... 6 2 L I S T O F F I G U R E S Fi g ur e 1. B 7 8 4 1 0 0 3 D o s e A s si g n m e nt ................................................................................2 9 A P P E N D I C E S A p p e n di x 1. A b br e vi ati o n s ...................................................................................................... 8 4 A p p e n di x 2. T hr o m b oti c A d v er s e E v e nt s f or St o p pi n g Crit eri a ............................................. 8 7 P R O T O C O L S U M M A R Y St u d y B 7 8 4 1 0 0 3 i s a P h a s e 2 , o p e n -l a b el st u d y i n s u bj e ct s wit h s e v er e h e m o p hili a A or B, wit h or wit h o ut i n hi bit or s t o F a ct or VIII ( F VIII) or F a ct or I X ( FI X). T hi s st u d y i s d e si g n e d t o e v al u at e t h e s af ety, t ol er a bilit y a n d effi c a c y of l o n g -t er m pr o p h yl a xi s wit h P F-0 6 7 4 1 0 8 6, a m o n o cl o n al a nti b o d y t h at t ar g et s ti ss u e f a ct or p at h w a y i n hi bit or ( T F PI). T F PI i s a n a nt a g o ni st of t h e e xtri n si c c o a g ul ati o n p at h w a y . P F-0 6 7 4 1 0 8 6, t hr o u g h it s n e utr ali z ati o n of T F PI, i s e x p e ct e d t o i n cr e a s e c o a g ul ati o n a cti vit y i n s u bj e ct s wit h h e m o p hili a. S u bj e ct s t h at c o m pl et e st u d y B 7 8 4 10 0 2, a 3 -m o nt h P h a s e 1 b/ 2 st u d y of pr o p h yl a xi s tr e at m e nt wit h P F-0 6 7 4 1 0 8 6, ar e eli gi bl e t o e nr oll i nt o t hi s st u d y t o c o nti n u e pr o p h yl a xi s tr e at m e nt. St u d y B 7 8 4 1 0 0 3 will a s s e s s t h e s af et y, t ol er a bilit y a n d effi c a c y of P F - 0 6 7 4 1 0 8 6 u p t o a 3 6 5- d a y tr e at m e nt p eri o d at t h e l o w e st d o s e l e v el d et er mi n e d t o b e s af e a n d effi c a ci o u s i n st u d y B 7 8 4 1 0 0 2. S e v er e h e m o p hili a A or B p ati e nt s ( F VIII or FI X a cti vit y  1 %), i n cl u di n g s u bj e ct s wit h i n hi bit or s t o F VIII or FI X, w h o di d n ot p arti ci p at e i n st u d y B 7 8 4 1 0 0 2 will al s o b e eli gi bl e f or e nr oll m e nt i n B 7 8 4 1 0 0 3. T w o c o h ort s of s u bj e ct s ( 6 s u bj e ct s p er c o h ort) will b e e nr oll e d t o pr o vi d e s u p pl e m e nt al l o n g -t er m s af et y, t ol er a bilit y, a n d effi c a c y d at a o n P F-0 6 7 4 1 0 8 6 i n a d e n o v o p o p ul ati o n. D e n o v o c o h ort s will b e o p e n t o t h e e nr oll m e nt of a d ol e s c e nt s e v er e h e m o p hili a p ati e nt s (  1 2 t o < 1 8 y e ar s of a g e) a n d s e v er e h e m o p hili a p ati e nt s wit h i n hi bit or s t o F VIII or FI X. Aft er all s u b c ut a n e o u s ( S C) c o h ort s h a v e c o m pl et e d 3 m o nt h s of tr e at m e nt i n st u d y B 7 8 4 1 0 0 2, t h e d e n o v o s u bj e cts will b e c o n si d er e d f or e nr oll m e nt i nt o B 7 8 4 1 0 0 3. All d e n o v o s u bj e ct s will b e a s si g n e d t o tr e at m e nt wit h P F - 0 6 7 4 1 0 8 6 f or a tr e at m e nt p eri o d of u p t o 3 6 5 d a y s, at t h e l o w e st d o s e l e v el d et er mi n e d t o b e s af e a n d effi c a ci o u s i n B 7 8 4 1 0 0 2. D uri n g t h e 3 6 5- d a y tr e at m e nt p eri o d, P F-0 6 7 4 1 0 8 6 will b e a d mi ni st er e d s u b c ut a n e o u sl y. All s u bj e ct s will b e r e q uir e d t o att e n d m o nt hl y cli ni c vi sit s d uri n g t h e 3 6 5- d a y tr e at m e nt p eri o d ( D a y 1 t o D a y 3 6 5) a n d o n e m o nt h f oll o w -u p ( D a y 3 9 3). C CI S u bj e ct s w h o c o m pl et e d st u d y B 7 8 4 1 0 0 2 will b e all o w e d t o s elf -a d mi ni st er tr e at m e nt at h o m e aft er tr ai ni n g b y t h e sit e a n d d e m o n str ati o n of a bilit y t o s elf-a d mi ni st er b y t h e s u bj e ct. D e n o v o s u bj e ct s will b e all o w e d t o s elf-a d mi ni st er f oll o wi n g t h e D a y 2 9 vi sit, aft er tr ai ni n g b y t h e sit e a n d d e m o n str ati o n of a bilit y t o s elf-a d mi ni st er b y t h e s u bj e ct. T hr o u g h D a y 3 6 5 d at a will b e r e vi e w e d t o d et er mi n e if P F - 0 6 7 4 1 0 8 6 i s s af e a n d w ell t ol er at e d at t h e r e s p e cti v e d o s e l e v el s. D o si n g of a n y s u bj e ct m a y b e st o p p e d if a v ail a bl e d at a i n di c at e t h at t h e tr e at m e nt i s n ot s af e a n d w ell- t ol er at e d. U p t o 3 6 s u bj e ct s ar e pl a n n e d t o b e tr e at e d i n st u d y B 7 8 4 1 0 0 3 ( 2 4 s u bj e ct s fr o m B 7 8 4 1 0 0 2 a n d 1 2 a d diti o n al d e n o v o s u bj e ct s). S u bj e ct s will p arti ci p at e i n t h e st u d y f or u p t o 1 5 m o nt h s, i n cl u di n g s cr e e ni n g a n d f oll o w - u p. s a m pl e si z e c al c ul ati o n i nf or mi n g c o h ort s a m pl e si z e or o v er all st u d y s a m pl e si z e. T h e c o h ort s a m pl e si z e s a n d o v er all st u d y s a m pl e si z e ar e b a s e d o n t h e n u m b er of s u bj e ct s e nr oll e d i n st u d y B 7 8 4 1 0 0 2, a n d o n cli ni c al c o n si d er ati o n s t o b al a n c e t h e n e e d t o mi ni mi z e e x p o s ur e of st u d y s u bj e ct s t o t h e i n v e sti g ati o n al pr o d u ct wit h t h e n e e d t o pr o vi d e a d e q u at e s af et y a n d t ol er a bilit y d at a f or cli ni c al d e v el o p m e nt. S af et y e n d p oi nt s will i n cl u d e tr e at m e nt e m er g e nt a d v er s e e ve nt s, i nf u si o n/i nj e cti o n sit e r e a cti o n s, s af ety C CI l a b or at or y p ar a m et er s. Pr o p h yl a xi s effi c a c y will b e a s s e s s e d b y c oll e cti n g t h e n u m b er of a c ut e bl e e di n g e pi s o d e s p er s u bj e ct d uri n g t h e tr e at m e nt p eri o d of u p t o 3 6 5 d a y s a n d d et er mi ni n g t h e a n n u ali z e d bl e e d r at e ( A B R). F or s u bj e ct s c o nti n ui n g fr o m st u d y B 7 8 4 1 0 0 2 o n t h e s a m e d o s e, t h e s e d at a m a y b e c o m bi n e d b et w e e n t h e st u di e s t o d et er mi n e t h e A B R. All d at a will b e s u m m ari z e d d e s cri pti v el y f or e a c h c o h ort a n d t h e o v er all st u dy. D e m o n str at i o n of s af et y, t ol er a bilit y a n d effi c a c y t h at s u p p ort s l o n g-t er m c hr o ni c tr e at m e nt o n a n a c c e pt a bl e d o si n g s c h e d ul e i s i nt e n d e d t o s u p p ort pr o gr e s si o n of P F - 0 6 7 4 1 0 8 6 t o s u b s e q u e nt i n v e sti g ati o n s i n p ati e nt s wit h s e v er e h e m o p hili a A or B. SCHEDULE OF ACTIVITIES The schedule of activities table provides an overview of the protocol visits and procedures. Refer to the STUDY PROCEDURES and ASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the protocol. The investigator may schedule visits (unplanned visits) in addition to those listed on the schedule of activities table, in order to conduct evaluations or assessments required to protect the well-being of the subject. Table 1. Screening, Day 1 to Day 393, All Subjects T a bl e 1. S c r e e ni n g, D a y 1 t o D a y 39 3, All S u bj e ct s S c r e e ni n g Cli ni c Visits E n d of P r ot o c ol St u d y A cti vit y Visit d Visit S c r e e n D a y 1 c D a y 2 9 D a y 5 7 D a y 8 5 D a y 1 1 3 D a y 1 4 1 D a y 1 6 9 D a y 1 9 7 D a y 2 2 5 D a y 2 5 3 D a y 2 8 1 D a y 3 0 9 D a y 3 3 7 D a y 3 6 5 D a y 3 9 3 I d e ntifi e ra i n gb ( M o nt h ( M o nt h 2) ( M o nt h 3) ( M o nt h ( M o nt h ( M o nt h 6) ( M o nth 7) ( M o nt h 8) ( M o nt h ( M o nt h 1 0) ( M o nt h 1 1) ( M o nt h 1 2) ( M o nt h ( M o nt h 1) 4) 5) 9) 1 3) 1 4) D a y + 1 d a y  2 d a y  5 d a ys  5 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys Visit wi n d o w -3 4 t o D a y - 1 C o ntr a c e pti o n X X X X X X X X X X X X X X X i nstr u cti o ns/ X c h e c k g Vit al Si g ns h X X X X X X X X X X X X X X X X Uri n al ysis i X X X X X X E C G X b X b X b S er u m X X X b X b X X X X i c h e mi str y H e m at ol o g y i X X X b X b X X X X C D 4 c ell c o u nt X C CI Fi bri n o g e n X X b X X X X C CI Pr ot hr o m bi n X X b X X X X ti m e ( P T) C ar di a c X b X b tr o p o ni n I F a ct or VIII a n d X X X X X X F a ct or I X a cti vit y F a ct or VIII or X b ,o F a c t or IX i n hi bit or l e v els (f or s u bj e cts wit h a h e m o p hili a hist or y of i n hi bit or o nl y) T a bl e 1. S c r e e ni n g, D a y 1 t o D a y 39 3, All S u bj e ct s S c r e e ni n g Cli ni c Visits E n d of P r ot o c ol St u d y A cti vit y Visit d Visit S c r e e n D a y 1 c D a y 2 9 D a y 5 7 D a y 8 5 D a y 1 1 3 D a y 1 4 1 D a y 1 6 9 D a y 1 9 7 D a y 2 2 5 D a y 2 5 3 D a y 2 8 1 D a y 3 0 9 D a y 3 3 7 D a y 3 6 5 D a y 3 9 3 I d e ntifi e ra i n gb ( M o nt h ( M o nt h 2) ( M o nt h 3) ( M o nt h ( M o nt h ( M o nt h 6) ( M o nth 7) ( M o nt h 8) ( M o nt h ( M o nt h 1 0) ( M o nt h 1 1) ( M o nt h 1 2) ( M o nt h ( M o nt h 1) 4) 5) 9) 1 3) 1 4) D a y + 1 d a y  2 d a y  5 d a ys  5 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys Visit wi n d o w -3 4 t o D a y - 1 Pr ot hr o m bi n X 2 0 2 1 0 m ut ati o n t esti n g F a ct or V X L ei d e n m ut ati o n t esti n g Li pi d pr ofil e i X Pr ot ei n C X a cti vit y/ Pr ot ei n S l e v el/ A TIII a cti vit y S er ol o g y: H Bs X A g, H B c A b , H C V A b a n d HI V C CI I n cl usi o n/ X X e x cl usi o n crit eri a r e vi e w Tr e at m e nt X assi g n m e nt I n v esti g ati o n al X W e e kl y a d mi nistr ati o n at h o m e or i n cli ni c m P r o d u ct        m      m a d mi nist r ati o n ( S C) S u bj e ct di ar y n X X X X X X X X X X X X X X X T a bl e 1. S c r e e ni n g, D a y 1 t o D a y 39 3, All S u bj e ct s S c r e e ni n g Cli ni c Visits E n d of P r ot o c ol St u d y A cti vit y Visit d Visit S c r e e n D a y 1 c D a y 2 9 D a y 5 7 D a y 8 5 D a y 1 1 3 D a y 1 4 1 D a y 1 6 9 D a y 1 9 7 D a y 2 2 5 D a y 2 5 3 D a y 2 8 1 D a y 3 0 9 D a y 3 3 7 D a y 3 6 5 D a y 3 9 3 I d e ntifi e ra i n gb ( M o nt h ( M o nt h 2) ( M o nt h 3) ( M o nt h ( M o nt h ( M o nt h 6) ( M o nth 7) ( M o nt h 8) ( M o nt h ( M o nt h 1 0) ( M o nt h 1 1) ( M o nt h 1 2) ( M o nt h ( M o nt h 1) 4) 5) 9) 1 3) 1 4) D a y + 1 d a y  2 d a y  5 d a ys  5 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys  7 d a ys Visit wi n d o w -3 4 t o D a y - 1 C oll e c t n u m b er X             X X of n e w bl e e di n g e pis o d es M o nit ori n g X             X X i nj e cti o n sit e r e a cti o ns S eri o us a n d X              X n o n- s eri o us a d v ers e e v e nt m o nit ori n g C o n c o mit a nt X              X tr e at m e nts A b br e vi ati o ns:  = o n g oi n g/ c o nti n u o us e v e nt; C CI ; a P T T = a cti v at e d p arti al t hr o m b o pl asti n ti m e ; E C G = el e ctr o c ar di o gr a m; H B c A b = h e p atitis B c or e a nti b o d y; H Bs A g = h e p atitis B s urf a c e a nti g e n; H C V A b = h e p atitis C a n ti b o d y; HI V = h u m a n i m m u n o d efi ci e n c y vir us; hr = h o urs; I P = i n v esti g ati o n al pr o d u ct; N/ A = n ot a p pli c a bl e; C CI ; P T /I N R = pr ot hr o m bi n ti m e/i nt er n ati o n al n or m ali z e d r ati o; C CI . a. D a y r el ati v e t o st art of st u d y tr e at m e nt ( D a y 1). b. S cr e e ni n g a n d a d diti o n al a cti viti es n ot e d a p pl y t o d e n o v o s u bj e cts w h o di d n ot p arti ci p at e i n B 7 8 4 1 0 0 2. Pl e as e s e e S e cti o n 6 f or a d diti o n al d et ails. c. F or s u bj e cts w h o c o m pl et e d st u d y B 7 8 4 1 0 0 2, i nf or m e d c o ns e nt pr o c e d ur es will o c c ur at t h e D a y 1 visit. T h e D a y 1 visit f or B 7 8 4 1 0 0 3 m a y o c c ur o n t h e s a m e d a y (s a m e visit t o t h e cli ni c) as t h e B 7 8 4 1 0 0 2 D a y 8 5 or D a y 1 1 3 visit. A ll D a y 1 ( or B 7 8 4 1 0 0 2 D a y 8 5 or D a y 1 1 3) bl o o d dr a ws m ust b e d o n e pri or t o a d mi nistr ati o n of I P. T h e f oll o wi n g c o n diti o ns a p pl y t o all D a y 1 a cti viti es:  I n cl usi o n/ e x cl usi o n crit eri a: Crit eri a s h o ul d b e r e vi e w e d ( a n d eli gi bilit y c o nfir m e d) at D a y 1 f or s u bje cts w h o c o m pl et e d B 7 8 4 1 0 0 2 m or e t h a n 3 0 d a ys pri or t o t h e s c h e d ul e d D a y 1 visit. Pl e as e s e e S e cti o n 6. 1 f or r e q uir e d pr o c e d ur es.  Tr e at m e nt assi g n m e nt: All s u bj e cts will b e r e q uir e d t o r e c ei v e a n e w s u bj e ct n u m b er f or t his st u d y. Ot h er pr o c e d ur es f or tr e at m e nt assi g n m e nt m a y n ot b e n e c ess ar y f or s u bj e cts w h o c o m pl et e d st u d y B 7 8 4 1 0 0 2. d. S e e S e cti o n 6. 2. 5 f or g ui d a n c e o n f oll o w-u p c o nt a ct, if n e c ess ar y. e. M e di c al hist or y d at a f or s u bj e cts fr o m st u d y B 7 8 4 1 0 0 2 will als o b e us e d f or s u bj e cts e nr olli n g i nt o B 7 8 4 1 0 0 3. R es ol v e d A Es fr o m B 7 8 4 1 0 0 2 m a y b e e nt er e d as a d diti o n al m e di c al hist or y, w h er e a p pli c a bl e. f. At D a y 1 t hr o u g h D a y 3 6 5 , a n d at t h e dis cr eti o n of t h e I n v esti g at or, li mit e d e x a mi n ati o ns b as e d o n si g ns a n d s y m pt o ms will b e p erf or m e d, if cli ni c ally i n di c at e d t o ass ess c h a n g es fr o m b as eli n e/ pr e vi o us visits of a n y o n g oi n g s y m pt o ms. g. I nstr u cti o ns will b e pr o vi d e d at S cr e e ni n g a n d D a y 1 visit; c o ntr a c e pti o n c h e c k will b e p erf or m e d at ot h er visits. h. Vit al si g ns t o b e ass ess e d i n cl u d e p uls e r at e, r es pir at or y r at e, or al t e m p er at ur e, a n d bl o o d pr ess ur e (s u pi n e). i. S e e S e cti o n 7. 1. 1 , T a bl e 3 , f or list of a n al yt es. Diff er e nti al h e m at ol o g y p a n el r e q uir e d at D a ys 1, 8 5, 1 6 9 a n d 3 3 7. C CI m. Pri or t o s elf -a d mi nistr ati o n, sit es m ust e ns ur e s u bj e cts ar e tr ai n e d o n I P a d mi nistr ati o n a n d st or a g e p er t h e I P m a n u al. D osi n g b et w e e n pl a n n e d cli ni c visits m a y b e a d mi nist er e d b y i n v esti g ati o n al sit e st aff u nti l t h e r es p e cti v e s u bj e ct h as b e e n pr o p erl y tr ai n e d i n s elf-a d mi nistr ati o n. Sit es s h o ul d f oll o w -u p ( e g, vi a p h o n e c all) t o e ns ur e c o m pli a n c e wit h a d mi nistr ati o n i nstr u cti o ns, w h er e n e c ess ar y. S u bj e cts w h o c o m pl et e d t h e D a y 1 9 7 ( M o nt h 7) visit pri or t o A m e n d m e nt 2 ( a n d e xt e nsi o n of tr e at m e nt d ur ati o n) ar e all o w e d t o r est art tr e at m e nt, b e gi n ni n g wit h D a y 2 2 5 ( M o nt h 8). H e m at ol o g y, c h e mistr y, a n d uri n al ysis r es ults fr o m D a y 1 6 9 ( M o nt h 6) s h o ul d b e r e vi e w e d a g ai nst i n cl usi o n/ e x cl usi o n crit eri a pri or t o t h e r e s u m pti o n of tr e at m e nt t o e ns ur e t h er e ar e n o e x cl usi o n ar y l a b or at or y a b n or m aliti es. D a y 3 3 7 ( M o nt h 1 2) will b e t h e fi n al visit w h er e I P is dis p e ns e d f or s elf- a d mi nistr ati o n . F or s u bj e cts b ei n g d os e d i n t h e cli ni c, 7 d a ys b ef or e D a y 3 6 5 is t h e fi n al d a y for d osi n g. n. S u bj e ct di ar y dis p e ns e d a n d/ or c oll e ct e d. S u bj e ct di ar y is r e vi e w e d, i n cl u di n g i nf or m ati o n a b o ut st u d y c o m pli a n c e, bl e e di n g ass ess m e nts (i n cl u di n g sit e a n d tr a u m ati c/s p o nt a n e o us) a n d i nj e cti o n sit e r e a cti o ns. At D a y 1, s u bj e cts will b e pr o vi d e d tr ai ni n g wit h r es p e ct t o filli n g o ut t h e di ar y i n cl u di n g ti mi n g a n d n at ur e of i nf or m ati o n t o b e e nt er e d. o. F VIII a n d FI X i n hi bit or l e v els m ust b e d et er mi n e d b y a l o c al l a b or at or y. A p ositi v e i n hi bit or t est r es ult will b e a b o v e t h e u p p er li mit of n or m al f or t h e ass a y. I n hi bit or t est r es ults fr o m u p t o 6 m o nt hs pri or t o D a y 1 m a y b e us e d t o m e et t his r e q uir e m e nt. T a bl e 2. D a y 2 t h r o u g h D a y 2 2: C CI a n d T r e at m e nt Vi sit s f o r D e N o v o S u bj e ct s P r ot o c ol A cti vit y Cli ni c Visits Visit I d e ntifi e r a D a y 2 D a y 4 D a y 8 D a y 1 5 D a y 2 2 Visit wi n d o w  1 d a y  1 d a y  2 d a y  2 d a y  2 d a ys Li mit e d p h ysi c al e x a mi n ati o n X X X X X C o ntr a c e pti o n i nstr u cti o ns/ c h e c k X X X X X C CI S er u m c h e mistr y X X X H e m at ol o g y X X X Pr ot hr o m bi n ti m e ( P T) X X X C ar di a c tr o p o ni n I X X X C CI I n v esti g ati o n al P r o d u ct X b X b X b a d mi nist r ati o n ( S C) S u bj e ct di ar y c X X X C oll e ct n u m b er of n e w bl e e di n g      e pis o d es M o nit ori n g i nj e cti o n sit e r e a cti o ns      A d v ers e e v e nt m o nit ori n g      C o n c o mit a nt tr e at m e nts      A b br e vi ati o ns:  = o n g oi n g/ c o nti n u o us e v e nt; C CI a. D a y r el ati v e t o st art of st u d y tr e at m e nt ( D a y 1). b. I P a d mi nistr ati o n o n D a y 8, D a y 1 5, a n d D a y 2 2 t o o c c ur at t h e cli ni c wit h tr ai ni n g o n I P s elf- a d mi nistr ati o n f or d e n o v o s u bj e cts. c. S u bj e ct di ar y dis p e ns e d a n d/ or c oll e ct e d. S u bj e ct di ar y is r e vi e w e d, i n cl u di n g i nf or m ati o n a b o ut st u d y c o m pli a n c e, i n v esti g ati o n al pr o d u ct i nf usi o ns, bl e e di n g ass ess m e nts (i n cl u di n g sit e a n d tr a u m ati c/s p o nt a n e o us) a n d i nj e cti o n sit e r e a cti o ns. At D a y 1, s u bj e cts will b e pr o vi d e d tr ai ni n g wit h r es p e ct t o filli n g o ut t h e di ar y i n cl u di n g ti mi n g a n d n at ur e of i nf or m ati o n t o b e e nt er e d. 1. INTRODUCTION 1.1. Mechanism of Action/Indication PF-06741086 is a human monoclonal immunoglobulin of the G isotype, subclass 1 (IgG1) that targets the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI). PF-06741086 is in development as a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in individuals with severe hemophilia A or B with or without inhibitors. Protocol B7841003 is a long-term study on the safety, tolerability and efficacy of PF-06741086 during up to 365 days of treatment. Satisfactory safety, tolerability, and efficacy data from this study are intended to support the development of PF-06741086 as a treatment in hemophilia. 1.2. Background and Rationale The current standard of care for treatment of individuals with hemophilia A or B is replacement of their deficient clotting factor using Factor VIII (FVIII) or Factor IX (FIX) clotting factor concentrate, respectively.1 This replacement therapy is administered to treat or prevent acute bleeding episodes, to provide hemostasis during surgery, invasive procedures and the subsequent wound healing period, or to provide routine prophylaxis to prevent bleeding episodes. However, a subset of patients with hemophilia develop neutralizing antibodies (inhibitors) directed against FVIII or FIX, reducing the effectiveness of factor replacement therapy as a first-in-line therapy for prophylaxis against or treatment of hemophilia bleeding episodes.2 For patients who respond to clotting factor replacement, the intravenous (IV) administration route and frequency of infusion required for effective prophylaxis treatment remains burdensome, and may result in reduced adherence to the treatment schedule and compromised prophylactic efficacy. As well, venous access for IV administration of clotting factor concentrates is limited in the youngest pediatric patients with hemophilia. In these patients, indwelling central venous catheters are frequently required to assure venous access with the attendant infectious and thrombotic complications. Thus, an unmet medical need exists for a standalone SC or low frequency IV intervention to promote hemostasis and coagulation in patients with hemophilia in lieu of coagulation factor replacement therapy. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor-activated coagulation Factor VII (FVIIa) and activated Factor X (FXa).3 TFPI has two isoforms, TFPIα and TFPIβ. The two isoforms share two of the same Kunitz-type domains (K1 and K2), but TFPIβ lacks the K3 domain. Isoforms are distributed in plasma and on vascular endothelial cell surfaces through glycosylphosphatidylinositol anchors. TFPIα is also located in platelets. Available data indicates that a reduced quantity of TFPI in plasma is associated with faster coagulation times and increased thrombin generation.4 Individuals with TFPI free antigen at the 5th percentile and 2nd percentile have an odds ratio for deep vein thrombosis that is 2.1- and 2.2-fold that of the general population, respectively, indicating a wide therapeutic index is associated with modulation of TFPI activity.5 Additionally, single doses of PF-06741086 have been evaluated in a Phase 1 first-in-human study without significant pharmaceutical treatment to reduce inhibition of the extrinsic coagulation pathway and thereby increase clotting activity in patients with bleeding disorders, such as hemophilia. 1.2.1. Nonclinical Pharmacology and Pharmacokinetics Analysis at the molecular level demonstrated that PF-06741086 targets an epitope in the K2 domain. Surface Plasmon Resonance (SPR) was used to characterize PF-06741086 binding affinity and kinetics of binding to human, cynomolgus monkey, rabbit, mouse, and rat TFPI and was in the low-nanomolar to sub-nanomolar range. The neutralization of TFPI by PF-06741086 was measured using a number of in vitro functional assays. The analysis included FXa chromogenic activity assays which measure reversal of TFPI inhibition of Factor Xa or FXa/FVIIa/TF complex in purified systems. PF-06741086 promoted hemostasis in hemophilic plasma from hemophilia A, B, and hemophilia inhibitor plasma and in non-hemophilic plasma as measured in thrombin generation assays (TGA), and dilute prothrombin time (dPT) assays. PF-06741086 inhibitory activity was also demonstrated using thromboelastography (TEG) performed on whole non-hemophilic blood. PF-06741086 also improved the thrombin generation response of severe hemophilia plasma dosed with rFVIIa. The efficacy of PF-06741086 was demonstrated in injury models of hemostasis using Factor VIII deficient mice (model of hemophilia A) and Factor IX deficient mice (model of hemophilia B). PF-06741086 restored hemostasis in hemophilia mouse injury models when administered before and after the onset of a bleeding injury. The pharmacodynamic profile of PF-06741086 is consistent with its TFPI inhibitory activity. The cumulative pharmacodynamic and potential additive effects of the combined, repeated dose administration of PF-06741086 and NovoSeven®RT (rFVIIa) was evaluated in rats in a 10-day IV investigative study. Combined, repeated dose administration of PF-06741086 at 50 mg/kg and NovoSeven RT at 3 mg/kg to rats was associated microscopically with an increased incidence and/or severity of minimal to mild, acute thrombi/emboli in the lung and injection site (tail) without any microscopic evidence of secondary tissue injury or effects on the animals’ clinical condition in the main study animals. These findings were not observed with the same incidence/severity with either test article administration at the same doses alone or in combination when administered as PF-06741086 at 50 mg/kg and NovoSeven RT at 0.8 (0.4 BID) mg/kg indicating a greater effect of combined administration of PF-06741086 and NovoSeven RT at 50 and 3 mg/kg, respectively. Administration of Novoseven RT at any dose alone or in combination with PF-06741086 resulted in test article-, non-dose-related lower group means for PT. The magnitude of the change was not significantly altered by co-administration of PF-06741086. Thrombi/emboli formation and shortening of PT are consistent with the pharmacology of both test articles. There was 1 test article-related unscheduled moribund euthanasia of an animal in the PF-06741086 (50 mg/kg)/NovoSeven RT (3 mg/kg)-dose pharmacokinetic group on Day 8 within 2 hours of the first Novoseven RT dose because of bilateral hindlimb paralysis related to acute thrombi/emboli in the iliac arteries; acute thrombi/emboli were also observed in other tissues. This animal also had ileal and cecal erosions of uncertain etiology, which may have contributed to the animal’s hypercoagulable state. The systemic exposure of NovoSeven RT observed in rats at 0.4, 1, and 3 mg/kg was equivalent or greater than the aprdeddiiticto en,d tchlie nio cbasle revxepdo sduarile yo ft otNaol veoxSpeovseunr e R oTf atN o3 v0,o S9 e0,v ea nn Rd T2 7at0 0.8g/ (k 0g. r4eBsIp De)ctimvge/lkyg. iIn n r at s w a s a p p r o xi m at el y e q ui v al e nt t o t h e pr e di ct e d t ot al d ail y cli ni c al e x p o s ur e aft er 3 d o s e s of N o v o S e v e n R T at 9 0  g/ k g. S y st e mi c e x p o s ur e s c h ar a ct eri z e d b y C a n d A U C f or m a x t P F - 0 6 7 4 1 0 8 6 a n d N o v o S e v e n R T w er e n ot aff e ct e d b y c o m bi n e d t e st arti cl e a d mi ni str ati o n. S e p ar at e s af et y p h ar m a c ol o g y st u di e s w er e n ot c o n d u ct e d wit h P F -0 6 7 4 1 0 8 6, b ut s af et y p h ar m a c ol o g y e n d p oi nt s e v al u ati n g t h e p ot e nti al eff e ct s of P F-0 6 7 4 1 0 8 6 o n t h e r e s pir at or y , c ar di o v a s c ul ar ( C V), a n d c e ntr al n er v o u s s ys t e m s ( C N S) w er e i n cl u d e d i n t h e 1 3-w e e k t o xi cit y st u d y i n m o n k e y s. 1. 2. 2. N o n cli ni c al T o xi c ol o g y T h e t o xi cit y of i ntr a v e n o u sl y or s u b c ut a n e o u sly a d mi ni st er e d P F -0 6 7 4 1 0 8 6 w a s e v al u at e d i n n o n pi v ot al C CI 8 -d a y , r e p e at-d o s e st u di e s i n r at s a n d m o n k e y s a n d pi v ot al ( G LP) st u di e s i n r at s a n d m o n k e y s of u p t o 6 or 3 m o nt h s i n d ur ati o n, r e s p e cti v el y. T h e I V a n d S C r o ut e s of a d mi ni str ati o n w er e s el e ct e d f or t h e s e st u di e s si n c e t h e y ar e t h e i nt e n d e d r o ut e s of cli ni c al e x p o s ur e. R at s a n d m o n k e y s w er e c h o s e n a s t h e n o n cli ni c al s p e ci e s b e c a u s e P F - 0 6 7 4 1 0 8 6 bi n d s t o T F PI i n t h e s e s p e ci e s. T h e u s e of r at s a n d m o n k e y s i n n o n cli ni c al t o xi c ol o g y st u di e s i s f urt h er j u stifi e d b y e vi d e n c e of p h ar m a c ol o gi c al a cti vit y, s u c h a s d e cr e a s e s i n fi bri n o g e n ( FI B) a n d i n cr e a s e s i n D -di m er, i n b ot h s p e ci e s i n r e p e at -d o s e t o xi cit y st u di e s. B ot h s p e ci e s d e m o n str at e d dr u g e x p o s ur e f oll o wi n g I V or S C a d mi ni str ati o n s a n d t ar g et or g a n t o xi cit y ; t h er ef or e t h e r at w a s s uit a bl e f or u s e a s t h e o nly s p e ci e s f or e v al u ati n g c hr o ni c t o xi cit y . Ot h er t o xi cit y st u di e s i n cl u d e d ti s s u e cr o s s r e a cti vity a s s a y , F c R a n d C 1 q bi n di n g a s s a ys, a n d a c yt o ki n e r el e a s e a s s a y. G e n eti c t o xi cit y st u di e s w er e n ot c o n d u ct e d b e c a u s e t h e y ar e g e n er ally n ot a p pr o pri at e f or bi ot e c h n ol o g y- d eri v e d pr o d u ct s. T hi s n o n cli ni c al pr o gr a m i s i nt e n d e d t o s u p p ort cli ni c al tri al s of u p t o 3 m o nt h s i n d ur ati o n. P F - 0 6 7 4 1 0 8 6 w a s a d mi ni st er e d t o r at s a n d m o n k e ys b y i ntr a v e n o u s (I V) a n d s u b c ut a n e o u s ( S C) i nj e cti o n, i n st u di e s u p t o 2 6 w e e k s i n d ur ati o n. W h e n a d mi ni st er e d w e e kl y t o r at s f or 2 6 w e e k s at d o s e s u p t o 1 0 0 0 m g/ k g/ d o s e, t h e n o o b s er v e d a d v er s e eff e ct l e v el ( N O A E L) w a s 1 0 0 0 m g/ k g/ d o s e, c orr e s p o n di n g t o a C of 2 9, 8 0 0, 0 0 0 n g/ m L a n d a n A U C of m a x 1 6 8 1, 8 4 0, 0 0 0, 0 0 0 n g· h/ m L. I n r at s, at 1 0 0 0 m g / k g/ d o s e I V, C ( 2 9, 8 0 0, 0 0 0 n g/ m L) a n d m a x A U C ( 1, 8 4 0, 0 0 0, 0 0 0 n g• h/ m L) o n D a y 1 7 6 w er e 9 5 x a n d 6 9 x t h e pr e di ct e d h u m a n 1 6 8 e x p o s ur e at t h e hi g h e st i nt e n d e d I V d o s e of 1 0 0 0 m g o n c e m o nt hl y ( Q M) ( C = 3 1 3, 0 0 0 n g/ m L a n d A U C = 2 6, 6 0 0, 0 0 0 n g• h/ m L). W h e n a d mi ni st er e d o n c e m a x 1 6 8 w e e kl y f or 1 3 w e e k s, t h e n o o b s er v e d a d v er s e eff e ct l e v el s ( N O A E L s) w er e 1 0 0 0 m g/ k g/ d o s e I V a n d 1 8 0 m g/ k g/ d o s e S C i n r at s a n d 5 0 0 m g/ k g/ d o s e I V a n d 9 0 m g/ k g/ d o s e S C i n m o n k e y s. I n r at s, at 1 0 0 0 m g / k g/ d o s e I V, C ( 2 7, 8 0 0, 0 0 0 n g/ m L) m a x a n d A U C ( 1, 9 4 0, 0 0 0, 0 0 0 n g• h/ m L) o n D a y 8 5 w er e 8 9 x a n d 7 3 x t h e pr e di ct e d h u m a n 1 6 8 e x p o s ur e at t h e hi g h e st i nt e n d e d I V d o s e a n d at 1 8 0 m g/ k g/ d o s e S C, C ( 4 1 6, 0 0 0 n g/ m L) m a x a n d A U C ( 4 5, 3 0 0, 0 0 0 n g• h/ m L) o n D a y 8 5 w er e 3 x a n d 2 x t h e pr e di ct e d h u m a n e x p o s ur e 1 6 8 at t h e hi g h e st i nt e n d e d S C d o s e of 4 5 0 m g o n c e w e e kl y ( Q W) ( C = 1 3 4, 0 0 0 n g/ m L a n d m a x A U C = 2 1, 5 0 0, 0 0 0 n g• h/ m L ). I n m o n k e ys, at 5 0 0 m g/ k g/ d o s e I V, 1 6 8 C ( 1 8, 4 0 0, 0 0 0 n g/ m L) a n d A U C ( 2, 0 0 0, 0 0 0, 0 0 0 n g• h/ m L) o n D a y 8 5 w er e 5 9 x a n d 75x the predicted human exposure at the highest intended IV dose and at 90 mg/kg/dose SC, C (2,480,000 ng/mL) and AUC (364,000,000 ng•h/mL) on Day 85 were 19x and 17x max 168 the predicted human exposure at the highest intended SC dose. Anticipated staining in the endothelium and placental decidual cells and trophoblasts was observed in the tissue cross reactivity assay. In the C1q binding and FcR binding assays, PF-06741086 did not bind to C1q, suggesting an inability to activate the classical complement pathway and induce CDC, and FcR binding assays showed that PF-06741086 had low potential to elicit ADCC activity. In the cytokine release assay, PF-06741086 did not elicit a test article-related release of TNF α, IL-6, or IFN-γ. When administered to rats as a single SC dose of 300 mg/kg, the NOAEL in the 1-day local toleration study with a 1-week recovery was 300 mg/kg SC, corresponding to a C (1,390,000 ng/mL) and AUC (139,000,000 ng•h/mL) with max 168 10x and 7x the predicted human exposure at the highest intended SC dose. The potential target organs identified in these studies was the coagulation cascade based on changes in D-dimer, PT, APTT and fibrinogen, with no clinical signs or microscopic evidence of bleeding or adverse thrombi/emboli formation. However, there were other effects on ALB, GLOB, ALB:GLOB and total protein values of rats and monkeys, the SC injection site of rats, and ADA’s were observed in rats. Consistent with ICH S6 guidance, PF-06741086 was not evaluated in genotoxicity studies because it is not expected that this large molecule would interact directly with DNA or other chromosomal material. 1.2.3. Clinical Experience with PF-06741086 To date, a single clinical study has been completed with PF-06741086. The clinical development of PF-06741086 began with study B7841001: a Phase 1, first-in-human (FIH) single ascending dose (SAD) study in healthy subjects. Male subjects between the ages of 18 and 55 with no known risk factors for thrombosis were eligible for this study. Subjects were enrolled sequentially into cohorts ordered by PF-06741086 maximum single-dose concentration and randomized to receive a single SC or IV dose of PF-06741086 or placebo. Data on safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity were collected during clinic confinement (7 days) and outpatient follow-up (up to 84 days). In study B7841001, there were no significant adverse effects following single dose administration with PF-06741086. There were no serious adverse events (SAEs). There were no severe adverse events (AEs). There were no clinically significant changes in laboratory parameters. Additional clinical information regarding PF-06741086 including data from study B7841001 may be found in the Investigator Brochure. The second clinical investigation of PF-06741086 is ongoing with study B7841002, an open-label, Phase 1b/2, multiple ascending dose (MAD) study in severe hemophilia A or B, with or without inhibitors to FVIII or FIX. The clinical risk/benefit profile for this population is considered appropriate for the evaluation of safety, tolerability, PK, PD, and efficacy of multiple doses of PF-06741086. a s c e n di n g d o s e s of P F- 0 6 7 4 1 0 8 6 a d mi ni st er e d b y t h e S C. S e c o n d ar y o bj e cti v e s i n cl u d e e v al u ati n g t h e P K a n d P D pr o p erti e s of P F -0 6 7 4 1 0 8 6 , a s w ell a s a s s e s si n g cli ni c al effi c a c y b a s e d o n t h e fr e q u e n c y of bl e e di n g e pi s o d e s. It i s e x p e ct e d t h at at l e a st o n e d o s e l e v el i n st u d y B 7 8 4 1 0 0 2 will a c hi e v e pr o p h yl a xi s effi c a c y o ut c o m e s s uffi ci e nt t o s u p p ort f urt h er cli ni c al d e v el o p m e nt, i n cl u di n g st u d y B 7 8 4 1 0 0 3. I nt eri m cli ni c al d at a fr o m st u d y B 7 8 4 1 0 0 2 m a y b e f o u n d i n t h e P F-0 6 7 4 1 0 8 6 I nv e sti g at or Br o c h ur e. 1. 2. 4. B 7 8 4 1 0 0 3 St u d y R ati o n al e T h e cli ni c al i n v e sti g ati o n of P F - 0 6 7 4 1 0 8 6 will c o nti n u e wit h st u d y B 7 8 4 1 0 0 3, a l o n g-t er m st u d y o n t h e s af ety, t ol er a bil it y a n d effi c a c y of P F- 0 6 7 4 1 0 8 6 u p t o 3 6 5 d a y s of tr e at m e nt. T h e pri m ar y o bj e cti v e of st u d y B 7 8 4 1 0 0 3 i s t o e v al u at e t h e s af et y a n d t ol er a bilit y of l o n g-t er m ( u p t o 3 6 5 d a y s ) pr o p hyl a xi s wit h P F - 0 6 7 4 1 0 8 6 a d mi ni st er e d b y t h e S C r o ut e. T h e s e c o n d ar y o bj e ctiv e i s t h e a s s e s s m e nt of cli ni c al effi c a c y b a s e d o n t h e fr e q u e n c y of bl e e di n g e pi s o d e s. C CI S af et y d at a i n cl u di n g tr e at m e nt-e m er g e nt A E s a n d l a b or at or y a b n or m aliti e s will b e r e vi e w e d t hr o u g h o ut t h e st u dy t o m o nit or a n y u n a nti ci p at e d ri s k s a s s o ci at e d wit h P F - 0 6 7 4 1 0 8 6 tr e at m e nt. D e m o n str ati o n of s af et y, t ol er a bilit y a n d effi c a c y t h at i s s u p p orti v e f or l o n g-t er m c hr o ni c tr e at m e nt o n a n a c c e pt a bl e d o si n g s c h e d ul e i s i nt e n d e d t o s u p p ort pr o gr e s si o n of P F -0 6 7 4 1 0 8 6 t o s u b s e q u e nt i n v e sti g ati o n s i n p ati e nt s wit h s e v er e h e m o p hili a A or B. 1. 2. 5. D o s e R ati o n al e S u bj e ct s e nr olli n g i n B 7 8 4 1 0 0 3 fr o m C o h ort 1 ( 3 0 0 m g S C) of B 7 8 4 1 0 0 2 will c o nti n u e wit h t h eir a ssi g n e d d o s e l e v el at t h e c o m pl eti o n of B 7 8 4 1 0 0 2. All ot h er s u bj e ct s e nr olli n g i n st u d y B 7 8 4 1 0 0 3 (f oll o wi n g p arti ci p ati o n i n B 7 8 4 1 0 0 2) will r e c ei v e t h e l o w e st S C d o s e l e v el d et er mi n e d t o b e s af e a n d effi c a ci o u s i n st u d y B 7 8 4 1 0 0 2 f or t h e r e sp e cti v e h e m o p hil i a p o p ul ati o n: 3 0 0 m g S C l o a di n g d o s e o n D a y 1, f oll o w e d b y 1 5 0 m g S C Q W f or n o n-i n hi bit or s u bj e ct s; 3 0 0 m g S C Q W f or i n hi bit or s u bj e ct s. D e n o v o s u bj e ct s i n C o h ort 5 ( a d ol e s c e nt s wit h or wit h o ut i n hi bit or s) a n d C o h ort 6 ( a d ult s wit h i n hi bit or s) will r e c ei v e a 3 0 0 m g S C l o a di n g d o s e o n D a y 1, f oll o w e d b y 1 5 0 m g S C Q W. All d o s e s will b e a d mi ni st er e d b y t h e S C r o ut e. 1. 2. 6. S u m m a r y of Ri s k/ B e n efit B a s e d o n t h e p ot e nti al ri s k s, s u bj e ct s will b e m o nit or e d f or tr e at m e nt e m er g e nt e v e nt s u si n g p ar a m et er s t h at i n cl u d e: s er u m c h e mi str y , h e m at ol o g y, uri n alys i s; vit al si g n s; p h ysi c al e x a mi n ati o n s; a n d a d v er s e e v e nt s. M o nit ori n g f or a nti b o d y i m m u n e r e s p o n s e will u s e a ti er e d t e sti n g str at e g y i n cl u di n g m e a s ur e m e nt of A D A t o P F- 0 6 7 4 1 0 8 6 a n d f urt h er c h ar a ct eri z ati o n of a n y p o si ti v e a nti b o d y i m m u n e r e s p o n s e s s u c h a s t e sti n g f or n e utr ali zi n g cli ni c all y -r el e v a nt eff e ct s t h at m a y i m p a ct h e m o st a si s. S af et y h a s b e e n d e m o n str at e d at all t e st e d si n gl e d o s e l e v el s i n t h e B 7 8 4 1 0 0 1 FI H st u d y. F urt h er s af et y a n d t ol er a bilit y t e sti n g i s o n g oi n g i n t h e 3-m o nt h B 7 8 4 1 0 0 2 st u d y i n s u bj e ct s wit h h e m o p hili a. S u bj e ct s c o nti n ui n g o n t o st u d y B 7 8 4 1 0 0 3 fr o m B 7 8 4 1 0 0 2 will o nl y b e all o w e d t o d o s o at a d o s e l e v el a n d r o ut e of a d mi ni str ati o n t h at w a s d et er mi n e d t o b e s af e a n d w ell -t ol er at e d i n st u d y B 7 8 4 1 0 0 2. D e n o v o s u bj e ct s e nr olli n g i n st u d y B 7 8 4 1 0 0 3 will o nl y b e a s si g n e d t o P F-0 6 7 4 1 0 8 6 tr e at m e nt at t h e l o w e st S C d o s e l e v el d et er mi n e d t o b e s af e a n d effi c a ci o u s f or t h e r e s p e cti v e h e m o p hili a p o p ul ati o n ( n o n -i n hi bit or or i n hi bit or) i n st u d y B 7 8 4 1 0 0 2. F urt h er, d e n o v o s u bj e ct s will o nl y b e eli gi bl e f or e nr oll m e nt f oll o wi n g c o m pl eti o n of all S C c o h ort s t hr o u g h 3 m o nt h s of tr e at m e nt i n B 7 8 4 1 0 0 2. P o s si bl e ri s k s fr o m l o n g -t er m tr e at m e nt wit h P F-0 6 7 4 1 0 8 6 i n cl u d e t h e p ot e nti al f or t hr o m b o e m b oli c a n d i s c h e mi c e v e nt s, hy p er s e n siti vit y r e a cti o n s (i n cl u di n g l o c al i nj e cti o n/i nf u si o n sit e r e a cti o n s), a n d a nti b o dy i m m u n e r e s p o n s e wit h f or m ati o n of a nti -dr u g a nti b o di e s. H o w e v er, it i s e x p e ct e d t h at t h e p ot e nti al ri s k of a t hr o m b o e m b oli c or i s c h e mi c e v e nt i n s u bj e ct s wit h h e m o p hili a will b e l o w d u e t o t h e eff e ct s of F VIII or FI X d efi ci e n c y . T h e p ot e nti al t h er a p e uti c effi c a c y of pr o p h yl a xi s wit h P F- 0 6 7 4 1 0 8 6 m a y b e r efl e ct e d i n a r e d u c e d fr e q u e n c y of bl e e di n g e pi s o d e s v er s u s t h e n at ur al hi st or y of bl e e di n g e pi s o d e s f or s u bj e ct s u si n g F VIII or FI X r e pl a c e m e nt t h er a p y, or b y p a s s a g e nt t h er a p y, f or o n -d e m a n d tr e at m e nt of bl e e di n g e pi s o d e s. F urt h er, it i s a s s u m e d t h at a ny o c c urr e n c e of n e utr ali zi n g a nti b o di e s a g ai n st P F -0 6 7 4 1 0 8 6 will h a v e n o i m p a ct o n pr o p h yl a cti c tr e at m e nt wit h F VIII or FI X r e pl a c e m e nt. T h e s e a nti ci p at e d b e n efit s m a y j u stif y t h e p ot e nti al ri s k s of tr e at m e nt wit h P F - 0 6 7 4 1 0 8 6 f or s u bj e ct s wit h h e m o p hili a A or B wit h o ut i n hi bit or s c urr e ntl y r e c ei vi n g f a ct or r e pl a c e m e nt t h er a p y, a n d s u bj e ct s wit h i n hi bit or s c urr e ntly r e c ei vi n g b y p a s s a g e nt t h er a py. A d diti o n al i nf or m ati o n f or t hi s c o m p o u n d m a y b e f o u n d i n t h e si n gl e r ef er e n c e s af ety d o c u m e nt ( S R S D), w hi c h f or t hi s st u d y i s t h e I n v e sti g at or s Br o c h ur e. C CI P ri m a r y O bj e cti v e(s): P ri m a r y E n d p oi nt(s):  T o d et er mi n e t h e s af et y a n d t ol er a bilit y of  Fr e q u e n c y , s e v erit y a n d c a us al r el ati o ns hi p of l o n g-t er m tr e at m e nt ( u p t o 3 6 5 d a y s) wit h tr e at m e nt e m er g e nt a d v ers e e v e nts ( T E A Es); P F -0 6 7 4 1 0 8 6 i n s e v er e h e m o p hili a A a n d B D a y 1 u p t o D a y 3 9 3. s u bj e cts wit h or wit h o ut i n hi bit ors t o FVIII or FI X.  Fr e q u e n c y a n d m a g nit u d e of a b n or m al l a b or at or y fi n di n gs (i n cl u di n g h e m at ol o g y, c h e mistr y, uri n al y sis); D a y 1 u p t o D a y 3 9 3.  C h a n g es fr o m b as eli n e i n vit al si g n ( bl o o d pr ess ur e, p uls e r at e, t e m p er at ur e a n d r es pir ati o n r at e) m e as ur e m e nts a n d p h ysi c al e x a mi n ati o ns; D a y 1 u p t o D a y 3 9 3 a n d E C G D a y 1 t o D a y 2 9 i n d e n o v o s u bj e cts o nl y .  Fr e q u e n c y , s e v erit y a n d c as u al r el ati o ns hi p of i nf usi o n a n d i nj e cti o n sit e r e a cti o ns; D a y 1 u p t o D a y 3 9 3. S e c o n d a r y O bj e cti v e(s): S e c o n d a r y E n d p oi nt(s):  T o d et er mi n e t h e effi c a c y of l o n g-t er m tr e at m e nt  Fr e q u e n c y a n d a n n u ali z e d r at e of bl e e di n g wit h P F -0 6 7 4 1 0 8 6 i n s ev er e h e m o p hili a A a n d B e pis o d es; D a y 1 u p t o D a y 3 9 3. s u bj e cts wit h or wit h o ut i n hi bit ors t o FVIII or FI X.  Fr e q u e n c y of r es c u e ( FVIII, or FI X) t h er a p y f or tr e at m e nt of br e a kt hr o u g h bl e e di n g e pis o d es. T e rti a r y/ E x pl o r at o r y O bj e cti v e(s): T e rti a r y/ E x pl o r at o r y E n d p oi nt(s): C CI 3. STUDY DESIGN B7841003 is an open-label long-term (treatment of up to 365 days) evaluation of PF-06741086 as a prophylactic treatment regimen in subjects with hemophilia A or B, with or without inhibitors to FVIII or FIX. Investigators, subjects, site staff and sponsor study team members will not be blinded to treatment assignment. Subjects will be assigned to treatment cohorts as indicated in Figure 1 below. Figure 1. B7841003 Dose Assignment Subjects enrolling in B7841003 from Cohort 1 (300 mg SC) of B7841002 will continue with their assigned dose level at the completion of study B7841002. All other subjects enrolling in B7841003 will receive the lowest dose level determined to be safe and efficacious for the respective hemophilia population in study B7841002. Subjects who complete study B7841002 may enroll immediately into study B7841003 at the B7841002 Day 85 or Day 113 visit. This visit will be Day 1 for the B7841003 Schedule of Activities. Procedures that are required at the B7841002 Day 85 or Day 113 visit do not need to be repeated for B7841003 Day 1. All subjects who complete study B7841002 are eligible for study B7841003, unless a specific exclusion criterion in Section 4.2 is noted at the Day 1 visit. It is expected that some subjects who complete B7841002 may not be able to immediately enroll in B7841003. These subjects do not require a complete re-screening, however if there is a 30-day or longer gap between the B7841002 last study visit and the B7841003 Day 1 visit, the investigator must review the criteria in Section 4.1 and Section 4.2, perform the limited set of procedures listed in Section 6.1 and confirm that the subject still meets eligibility criteria. Subjects who completed the Day 197 (Month 7) visit prior to Amendment 2 (and extension of treatment duration) are allowed to restart treatment, beginning with Day 225 (Month 8). Hematology, chemistry, and urinalysis results from Day 169 (Month 6) should be reviewed against inclusion/exclusion criteria prior to the resumption of treatment to ensure there are no exclusionary laboratory abnormalities. De novo subjects will be eligible for enrollment following completion of all subcutaneous cohorts (ie, after Cohort 3) through 3 months of treatment in B7841002. Dosing of any subject may be stopped if available data indicate that the treatment is not safe and well-tolerated. 3.1. Planned Number of Subjects Approximately 36 subjects (24 subjects from B7841002 and 12 additional de novo subjects) are planned for enrollment at approximately 20 study sites. 3.2. Study Duration Subjects who completed B7841002 within 30 days of B7841003 Day 1 will begin this study at Day 1 (no Screening visit). A limited Screening visit and eligibility criteria review is required prior to Day 1 for subjects who completed study B7841002 more than 30 days prior to the scheduled Day 1 visit. All Screening activities apply to de novo subjects who did not participate in B7841002. Screening procedures may be completed up to 35 days prior to the Day 1 visit for these subjects (ie, Day -34). All subjects that meet inclusion/exclusion criteria at Day 1 will be assigned to a treatment regimen and dosed. All subjects will return for clinic visits on Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225, Day 253, Day 281, Day 309, Day 337, Day 365 with follow-up and end-of-study procedures on Day 393. De novo subjects will undergo additional visits, as per Table 2 during the interval between Day 1 and Day 29. The total duration of the treatment period will be up to 365 days. Subjects not yet proficient in SC self-administration may have scheduled doses of PF-06741086 administered by investigational site staff or their properly trained designees during the interval(s) between planned study visits. S u bj e ct s w h o e x p eri e n c e a tr e at m e n t-r el at e d a d v er s e e v e nt (i n cl u di n g l a b a b n or m aliti e s) at a n y ti m e p oi nt will c o nti n u e t o b e f oll o w e d t hr o u g h r e s ol uti o n or st a bili z ati o n of t h e e v e nt a s a gr e e d u p o n b y t h e i n v e sti g at or a n d s p o n s or. T h e m a xi m u m t ot al d ur ati o n of t h e st u d y f or a s u bj e ct w h o c o m pl et e d B 7 8 4 1 0 0 2 will b e a p pr o xi m at el y 1 4 m o nt h s ( e x cl u di n g s cr e e ni n g a n d a n y i nt err u pti o n i n tr e at m e nt pri or t o a p pr o v al of A m e n d m e nt 2). T h e m a xi m u m t ot al d ur ati o n of t h e st u d y f or d e n o v o s u bj e ct s, fr o m i niti al s cr e e ni n g t o fi n al f oll o w- u p, will b e a p pr o xi m at el y 1 5 m o nt h s. 3. 3. D o s e M o difi c ati o n R ul e s f o r A d v e r s e E v e nt s D o si n g m a y b e st o p p e d, p a u s e d, or m o difi e d b a s e d o n t h e f oll o wi n g crit eri a:  D o si n g at t h e c urr e nt d o s e l e v el ( or hi g h er d o s e l e v el s) will b e p a u s e d f or a n y tr e at m e nt e m er g e nt t hr o m b oti c ev e nt ( s e e A p p e n di x 2 f or q u alif yi n g A E s) i n a s u bj e ct r e c ei vi n g P F-0 6 7 4 1 0 8 6, t o p er mit c h ar a ct eri z ati o n of t h e r e s p e cti v e e v e nt a n d c o m m u ni c ati o n t o r e g ul at or y a g e n ci e s w h er e r e q uir e d.  V e s s el o c cl u si o n r el at e d t o t h e i n s erti o n or pr e s e n c e of a c e ntr al v e n o u s c at h et er m a y b e e x cl u d e d fr o m t hi s crit eri o n aft er r e vi e w of t h e A E wit h t h e r e s p e cti v e i n v e sti g at or t o a s s e s s c a u s alit y a n d/ or cli ni c al si g nifi c a n c e.  D o si n g will b e p a u s e d ( a n d m a y r e s u m e at a l o w er d o s e aft er s p o n s or r e v i e w of s af et y d at a) if a s u bj e ct e x p eri e n c e s a tr e at m e nt e m er g e nt s e v er e or  Gr a d e 3 a d v er s e e v e nt wit h o ut r e s ol uti o n aft er r e p e at a d mi ni str ati o n wit h P F- 0 6 7 4 1 0 8 6, u nl e s s i n c o ntr o v erti bl y d u e t o e xtr a n e o u s c a u s e s. A n y s u bj e ct w h o m e et s t h e a b o v e crit eri a d uri n g tr e at m e nt wit h P F -0 6 7 4 1 0 8 6 will b e r e m o v e d fr o m t h e c urr e nt d o s e l e v el a n d dr o p p e d t o t h e n e xt l o w e st e x p o s ur e l e v el, u nl e s s t h e e v e nt( s) ar e i n c o ntr o v erti bl y d u e t o e xtr a n e o u s c a u s e s or ar e i n c o ntr o v erti bl y c o m pli c ati o n s of h e m o p hili a ( s e e S e cti o n 8. 2. 3 f or q u alif yi n g e v e nt s). 3. 3. 1. D o s e M o difi c ati o n R ul e s f o r B r e a kt h r o u g h Bl e e di n g E pi s o d e s D o si n g m a y b e m o difi e d t o t h e n e xt hi g h er p er mitt e d d o s e l e v el ( b a s e d o n st u d y B 7 8 4 1 0 0 2 s af et y r e s ult s) if a s u bj e ct e x p eri e n c e s i n cr e a s e d br e a kt hr o u g h bl e e di n g fr e q u e n c y t h at m e et s t h e f oll o wi n g crit eri a:  T w o s p o nt a n e o u s ( atr a u m ati c) bl e e di n g e pi s o d e s i nt o m aj or j oi nt s s u c h a s el b o w, a n kl e or k n e e j oi nt( s) a n d/ or ot h er t ar g et j oi nt s o v er a 4 w e e k ( 2 8 d a y ) p eri o d. O R  T hr e e or m or e s p o nt a n e o u s ( atr a u m ati c) bl e e di n g e pi s o d e s ( e g, 1 j oi nt a n d 2 s oft 4. SUBJECT ELIGIBILITY CRITERIA This study can fulfill its objectives only if appropriate subjects are enrolled. The following eligibility criteria are designed to select subjects for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular subject is suitable for this protocol. Subject eligibility should be reviewed and documented by an appropriate member of the investigator’s study team before subjects are included in the study. 4.1. Inclusion Criteria All subjects must meet the following inclusion criteria to be eligible for enrollment into the study. Subjects continuing from B7841002 within 30 days of the B7841003 - Day 1 visit do not require screening procedures to confirm eligibility: 1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative/parent(s)/legal guardian) has been informed of all pertinent aspects of the study. 2. Males ≥18 and <75 years of age. 3. Body Mass Index (BMI) ≥17.5 and ≤30.5 kg/m2 and total body weight ≥50 and ≤100 kg. a. For adolescents, the BMI must be ≥14 kg/m2 and total body weight must be ≥30 kg. 4. Diagnosis of severe hemophilia A or B (FVIII or FIX activity ≤1%). 5. If receiving therapy for human immunodeficiency virus (HIV) or active hepatitis infection, have stable disease and be on a stable regimen at the time of study entry (ie, stable dosing for at least 3 months before consent). 6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. The following inclusion criteria only apply to de novo subjects (Cohorts 5 and 6) only: 1. Adolescent males ≥12 to <18 years of age are eligible. 2. Patients with an episodic (on-demand) treatment regimen who are willing and able to washout from Factor VIII (for at least 72 hours) or Factor IX (for at least 96 hours) replacement therapy, or bypass agent therapy (for rFVIIa and activated prothrombin complex concentrate [APCC]: at least 72 hours; for other products: at least 5 half-lives) prior to Screening laboratory assessments of factor activity and have no plans to institute prophylactic factor or bypass agent treatment during the study period. 3. Had at least 6 acute bleeding episodes (spontaneous/traumatic) during the 6 month period prior to Screening. Surgical bleeding episodes do not apply to this criterion. 4. Subjects enrolled as Factor VIII or Factor IX inhibitor patients must have a positive inhibitor test result (above the upper limit of normal) at the local laboratory and must receive a bypass agent as primary treatment for bleeding episodes. A positive inhibitor test result will be above the upper limit of normal for the assay. Inhibitor test results from up to 6 months prior to Day 1 may be used to meet this requirement. 4.2. Exclusion Criteria Subjects with any of the following characteristics/conditions will not be included in the study: 1. Females. 2. Known coronary artery, thrombotic, or ischemic disease, or known severe, uncontrolled hypercholesterolemia. 3. Known hemostatic defect other than hemophilia A or B. 4. ATIII, Protein C, or Protein S deficiency, Factor V Leiden, Prothrombin 20210 mutation, or other known pro-thrombotic condition. 5. Regular, concomitant therapy with immunomodulating drugs (eg, intravenous immunoglobulin [IVIG], and routine systemic corticosteroids). 6. Currently receiving treatment for acute bleeding episodes with APCC (eg, Factor Eight Inhibitor Bypass Agent [FEIBA]) and cannot substitute treatment with rFVIIa at a dose level of approximately 90 μg/kg for the duration of the study. 7. Abnormal renal or hepatic function as defined by the following laboratory results at any time prior to Day 1: • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels >3 times the upper limit of normal (ULN). • Total bilirubin level >2 mg/dL (>35 μmol/L). • Serum albumin < the lower limit of normal (LLN). • Serum creatinine level >1.25 times the ULN. 8. Abnormal hematology values as defined by the following laboratory results at any time prior to Day 1: • Platelet count <100,000/μL. • Fibrinogen level < LLN. • Hemoglobin level <10 gm/dL. 9. Abnormal coagulation activity as defined by the following laboratory results at any time prior to Day 1: • Prothrombin time (PT) >1.25 times the ULN. 10. CD4 cell count ≤200/μL. 11. Known hypersensitivity (eg, latex allergy) or allergic reaction to hamster protein. 12. Known sensitivity to heparin or heparin induced thrombocytopenia. 13. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study. 14. Participation in other studies involving investigational drug(s) (excluding PF-06741086) within 30 days prior to study entry and/or during study participation. 15. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. 16. Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product. 17. Had major surgery, as judged by the investigator, within 3 months prior to the study or have elective surgery planned during the study (applies only to de novo subjects). 4.3. Randomization Criteria This study is not a randomized trial, but allocation to treatment will follow procedures similar to randomization (which may be referred to as enrollment). All subjects will be given PF-06741086. All subjects will be required to receive a new subject number for this study. Other procedures for treatment assignment may not be necessary for subjects who completed study B7841002. Subjects will be assigned a randomization number provided they have satisfied all eligibility criteria and the following enrollment criteria: 1. De novo subjects in B7841003 must washout from FVIII (for at least 72 hours) or FIX (for at least 96 hours) replacement therapy prior to the Day 1 visit laboratory testing for clotting factor activity level. Subjects cannot be enrolled or treated with investigational product if they have received treatment for an acute bleeding episode with FVIII or FIX replacement therapy within 72 hours or 96 hours, respectively, or rFVIIa or APCC (eg, FEIBA) bypass agent therapy within 72 hours (or for other products: 5 half-lives) of the Day 1 visit. If factor replacement or bypass agent therapy is required to treat a bleeding episode during the Screening period, then the subject may return for the Day 1 visit after completing the required washout period and remain eligible for study participation. See Section 6.1 for further Screening procedure guidance. 4.4. Lifestyle Requirements 4.4.1. Contraception All fertile male subjects who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must agree to use a highly effective method of contraception consistently and correctly for the duration of the active treatment period and for at least 28 days after the last dose of investigational product. A longer duration of contraception usage may be required if data warrant this change. The investigator or his or her designee, in consultation with the subject, will confirm that the subject has selected an appropriate method of contraception for the individual subject and his partner from the permitted list of contraception methods (see below) and will confirm that the subject has been instructed in its consistent and correct use. At time points indicated in the Schedule of Activities, the investigator or designee will inform the subject of the need to use highly effective contraception consistently and correctly and document the conversation and the subject’s affirmation in the subject’s chart (subjects need to affirm their consistent and correct use of at least 1 of the selected methods of contraception). In addition, the investigator or designee will instruct the subject to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the subject or the partner. Highly effective methods of contraception are those that, alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly (ie, perfect use) and include the following: 1. Established use of hormonal methods of contraception associated with inhibition of ovulation (eg, oral, inserted, injected, implanted, transdermal) provided the subject or male subject’s female partner plans to remain on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness. 2. Correctly placed copper-containing intrauterine device (IUD). 3. Male condom or female condom used WITH a separate spermicide product (ie, foam, gel, film, cream, or suppository). For countries where spermicide is not available or condom plus spermicide is not accepted as highly effective contraception, this option is not appropriate. 4. Male sterilization with absence of sperm in the postvasectomy ejaculate. 5. Bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusive procedure (provided that occlusion has been confirmed in accordance with the device’s label). NOTE: Sexual abstinence, defined as completely and persistently refraining from all heterosexual intercourse (including during the entire period of risk associated with the study treatments) may obviate the need for contraception ONLY if this is the preferred and usual lifestyle of the subject. All sexually active male subjects must agree to prevent potential transfer to and exposure of partner(s) to drug through ejaculate by using a condom consistently and correctly, beginning with the first dose of investigational product and continuing for at least 28 days after the last dose of investigational product. 4.5. Sponsor’s Qualified Medical Personnel The contact information for the sponsor's appropriately qualified medical personnel for the study is documented in the study contact list located in the supporting study documentation. To facilitate access to appropriately qualified medical personnel on study-related medical questions or problems, subjects are provided with a contact card. The contact card contains, at a minimum, protocol and investigational product identifiers, subject study numbers, contact information for the investigator site, and contact details for a contact center in the event that the investigator site staff cannot be reached to provide advice on a medical question or problem originating from another healthcare professional not involved in the subject’s participation in the study. The contact number can also be used by investigator staff if they are seeking advice on medical questions or problems; however, it should be used only in the event that the established communication pathways between the investigator site and the study team are not available. It is therefore intended to augment, but not replace, the established communication pathways between the investigator site and the study team for advice on medical questions or problems that may arise during the study. The contact number is not intended for use by the subject directly, and if a subject calls that number, he or she will be directed back to the investigator site. 5. STUDY TREATMENTS For the purposes of this study, and per International Conference on Harmonisation (ICH) guidelines, investigational product is defined as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference/comparator in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved For this study, the investigational product(s) is PF-06741086. 5.1. Allocation to Treatment The investigator’s knowledge of the treatment should not influence the decision to enroll a particular subject or affect the order in which subjects are enrolled. Allocation of subjects to treatment groups will proceed through the use of an interactive response technology (IRT) system (interactive Web-based response [IWR]). The site personnel (study coordinator or specified designee) will be required to enter or select information including but not limited to the user’s identification (ID) and password, the protocol number, and the subject number. The site personnel will then be provided with a treatment assignment, randomization number, and dispensable unit (DU) or container number when investigational product is being supplied via the IRT system. The IRT system will provide a confirmation report containing the subject number, randomization number, and DU or container number assigned. The confirmation report must be stored in the site’s files. The study-specific IRT reference manual will provide the contact information and further details on the use of the IRT system. 5.2. Subject Compliance Subjects will be permitted to self-administer PF-0674106 once they have demonstrated an understanding of the preparation and administration process at the site. Confirmation of a subject’s ability to perform preparation and administration must be documented in the site file. For self-administration of PF-06741086 at home, compliance will be captured and completed by the subject by completing the subject diary. Subjects will self-administer treatment weekly from the point of which they have demonstrated the capability to do so (as stated above) until Day 365 (see Section 3.2). Prior to self-administration, sites must ensure subjects are trained on IP administration and storage per the IP manual. Dosing between planned clinic visits may be administered by investigational site staff until the respective subject has been properly trained in self-administration. Sites should follow-up (eg, via phone call) to ensure compliance with administration instructions, where necessary. Day 337 (Month 12) will be the final visit where IP is dispensed for self-administration. For subjects being treated in the clinic, 7 days before Day 365 is the final date that IP is administered in the clinic. 5. 3. 1. D o s a g e F o r m( s) a n d P a c k a gi n g P F - 0 6 7 4 1 0 8 6 S ol uti o n f or I nj e cti o n ( 1 5 0 m g / m L) will b e s u p pli e d b y Pfi z er a s a g o o d m a n uf a ct uri n g pr a cti c e ( G M P) m a n uf a ct ur e d, st eril e li q ui d s ol uti o n f or i nj e cti o n p a c k a g e d i n a 6 m L gl a s s vi al s e al e d wit h a st o p p er a n d a n al u mi n u m s e al ( n o mi nal fill v ol u m e of 1. 0 m L ). T h e s e pr o d u ct s will b e s u p pli e d t o sit e s a s o p e n l a b el p a c k a g e d s u p pli e s f or s u b s e q u e nt u nit d o si n g. 5. 3. 2. P r e p a r ati o n a n d Di s p e n si n g T h e i n v e sti g ati o n al pr o d u ct will b e di s p e n s e d u si n g a n I RT dr u g m a n a g e m e nt s y st e m at e a c h vi sit fr o m D a y 1 t o D a y 3 3 7. A q u alifi e d st aff m e m b er will di s p e n s e t h e i n v e sti g ati o n al pr o d u ct vi a u ni q u e c o nt ai n er n u m b er s i n t h e c art o n s pr o vi d e d, a n d i n q u a ntiti e s a p pr o pri at e s o t h at s u bj e ct s s elf- a d mi ni st eri n g tr e at m e nt s at h o m e will r e c ei v e e n o u g h i n v e sti g ati o n al pr o d u ct t o c o v er t h e n u m b er of d o s e s u ntil t h e n e xt s c h e d ul e d cli ni c vi sit. T h e s u bj e ct/ c ar e gi v er s h o ul d b e i n str u ct e d t o m ai nt ai n t h e pr o d u ct i n t h e c art o n s pr o vi d e d, a n d t h e c art o n s s h o ul d n ot b e o p e n e d u ntil t h e i n v e sti g ati o n al pr o d u ct i s t o b e a dmi ni st er e d. S e e t h e I n v e sti g ati o n al Pr o d u ct M a n u al (I P M) f or i n str u cti o n s o n h o w t o pr e p ar e t h e i n v e sti g ati o n al pr o d u ct f or a d mi ni str ati o n. In v e sti g ati o n al pr o d u ct s h o ul d b e pr e p ar e d, w h e n n e c e s s ar y , a n d di s p e n s e d b y a n a p pr o pri at ely q u alifi e d a n d e x p eri e n c e d m e m b er of t h e st u d y st aff ( e g, p h ys i ci a n, n ur s e, p h ysi ci a n’ s a s si st a nt, n ur s e pr a ctiti o n er, p h ar m a c y a s si st a nt/t e c h ni ci a n, or p h ar m a ci st) a s all o w e d b y l o c al, st at e, a n d i n stit uti o n al g ui d a n c e. T h e s e r e q uir e m e nt s will n ot a p pl y f or s elf-a d mi ni str ati o n b y s u bj e ct s. 5. 4. A d mi ni st r ati o n I n v e sti g at or sit e p er s o n n el, t h e s u bj e ct a n d/ or t h e s u bj e ct’ s c ar e gi v er will a d mi ni st er i n v e sti g ati o n al pr o d u ct a c c or di n g t o t h e s u bj e ct di ar y. Sit e p er s o n n el will i n str u ct t h e s u bj e ct or d e si g n at e d p er s o n o n t h e pr o p er st er il e t e c h ni q u e t o pr e p ar e a n d a d mi ni st er a S C i nj e cti o n at h o m e. D uri n g t h e D a y 1 vi sit, t h e i niti al d o s e of i n v e sti g ati o n al pr o d u ct m u st b e a d mi ni st er e d i n t h e offi c e b y st u d y p er s o n n el, w hil e t h e s u bj e ct a n d/ or t h e s u bj e ct’ s c ar e gi v er o b s er v e s. F or all S C tr e at m e nt s, t h e n u m b er of i nj e cti o n s a n d i nj e cti o n sit e s will b e r e c or d e d. T h e pr ef err e d b o d y l o c ati o n s of t h e S C i nj e cti o n( s) ar e t h e fr o nt of t h e mi d dl e of t h e t hi g h, i n cl u di n g a nt er ol at er al, or o ut er ar e a of t h e u p p er ar m. Ot h er l o c ati o n s ( e g, a b d o me n) ar e a c c e pt a bl e if r e q uir e d. C CI M ulti pl e i nj e cti o n s s h o ul d u s e a u ni q u e sit e f or e a c h i nj e cti o n w h er e p o s si bl e, t o li mit t h e i nj e cti o n sit e v ol u m e t o 1 m L (i e, 1 m L i n ar m, 1 m L i n t hi g h f or a 2 m L , 2 i nj e cti o n d o s e). W h e n f e a si bl e, if m ulti pl e i nj e cti o n s ar e r e q uir e d, t h e si m ult a n e o u s u s e of b ot h ar m s ( e g, 1 m L i n l eft ar m a n d 1 m L i n ri g ht ar m) s h o ul d b e a v oi d e d. All s elf -a d mi ni str ati o n i nf or m ati o n will b e d o c u m e nt e d i n t h e s u bj e ct di ar y. 5.5. Investigational Product Storage The investigator or an approved representative, eg, pharmacist, will ensure that all investigational products at the clinical site are stored in a secured area with controlled access under required storage conditions and in accordance with applicable regulatory requirements. Investigational products should be stored in their original containers and in accordance with the labels. Any storage conditions stated in the SRSD will be superseded by the storage conditions stated on the product label. Site systems must be capable of measuring and documenting (for example, via a log), at a minimum, daily minimum and maximum temperatures for all site storage locations (as applicable, including frozen, refrigerated, and/or room-temperature products). This should be captured from the time of investigational product receipt throughout the study. Even for continuous-monitoring systems, a log or site procedure that ensures active evaluation for excursions should be available. The intent is to ensure that the minimum and maximum temperature is checked each business day to confirm that no excursion occurred since the last evaluation and to provide the site with the capability to store or view the minimum/maximum temperature for all non-working days upon return to normal operations. The operation of the temperature monitoring device and storage unit (for example, refrigerator), as applicable, should be regularly inspected to ensure they are maintained in working order. Any excursions from the product label storage conditions should be reported to Pfizer upon discovery. The site should actively pursue options for returning the product to the storage conditions described in the labeling, as soon as possible. Deviations from the storage requirements, including any actions taken, must be documented and reported to Pfizer. Once an excursion is identified, the investigational product must be quarantined and not used until Pfizer provides permission to use the investigational product. It will not be considered a protocol deviation if Pfizer approves the use of the investigational product after the temperature excursion. Use of the investigational product prior to Pfizer approval will be considered a protocol deviation. Specific details regarding information that the site should report for each excursion will be provided to the site. Site staff will instruct subjects on the storage requirements for take home medications, including how to report temperature excursions. 5.6. Investigational Product Accountability The investigator site must maintain adequate records documenting the receipt, use, loss, or other disposition of the investigational product supplies. All investigational products will be accounted for using a drug accountability form/record. All unused study drug must be returned to the investigator by the subject at every visit and at the end of the trial. 5.6.1. Destruction of Investigational Product Supplies The sponsor or designee will provide guidance on the destruction of unused investigational product (eg, at the site). If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by Pfizer, and all destruction must be adequately documented. 5.7. Concomitant Treatment(s) • Subjects will abstain from all prohibited concomitant medications, except for the treatment of adverse events or acute bleeding episodes as described in Section 5.7.1 of this protocol. • All concomitant treatments taken during the study must be recorded with indication, and start and stop dates of administration. All subjects will be questioned about concomitant treatments at each clinic visit. • For emergency or unplanned surgical interventions, investigators must contact the sponsor’s medical monitor as soon as possible to review concomitant treatments and any impact on subject participation. • Treatments taken within 28 days prior to informed consent being signed will be documented as a prior treatment. Treatments taken from date of signed informed consent will be documented as concomitant treatments. 5.7.1. Prohibited Medications Routine prophylaxis with FVIII or FIX replacement therapy, or bypass agent therapy (rFVIIa, APCC or emicizumab), is prohibited throughout the study for all subjects. FVIII (within 72 hours) or FIX replacement therapy (within 96 hours), or bypass agent therapy (rFVIIa or APCC: within 72 hours; for other products: 5 half-lives) before Screening is prohibited. Depending on the coagulation factor product in use, additional wash out time may be required prior to the screening assessments to achieve a factor activity level ≤1%. If a subject experiences an acute bleeding episode during this washout period requiring treatment with a FVIII or FIX replacement therapy, or bypass agent therapy, the subject is to be stabilized utilizing this regimen and a new washout period should be initiated. The regimen used to treat the episode should be recorded as a prior medication. FVIII (within 72 hours) or FIX replacement therapy (within 96 hours), or bypass agent therapy (for rFVIIa or APCC: at least 72 hours; for other products: 5 half-lives), before Day 1 treatment is also prohibited. If a subject experiences an acute bleeding episode during this washout period requiring treatment with a Factor VIII or IX replacement therapy, or bypass agent therapy, the subject is to be stabilized utilizing this regimen and a new washout period should be initiated. The regimen used to treat the episode should be recorded as a concomitant medication. All acute bleeding episodes between Screening and Day 1 must be Subjects who received treatment with extended half-life (EHL) FVIII or FIX products may require longer washout periods than those noted above; careful consideration by investigators should be given to the dose and half-life of these treatments prior to planning the duration of washout. Treatment with rFVIIa at a dose level greater than approximately 90 μg/kg, or administered at intervals more frequent than every 2 hours, is prohibited throughout the study. If a subject receiving investigational product is subsequently administered a rFVIIa dose greater than approximately 90 μg/kg, or requires dosing more frequently than every 2 hours the investigator must immediately contact the Sponsor’s medical monitor to discuss the case to determine if the respective subject should continue to receive IP, remain in the study, or be withdrawn immediately. Treatment with activated prothrombin complex concentrate (APCC, eg, FEIBA) is prohibited throughout the study. Subjects receiving such therapy who cannot substitute treatment with rFVIIa at the 90 μg/kg per dose are not to be enrolled into this study. Subjects who are treated with investigational product who are subsequently administered APCC therapy must be withdrawn from treatment with investigational product immediately. These subjects should be followed at all remaining clinic visits up to Day 393 to monitor for adverse events and any additional safety concerns. The use of immunomodulatory medications (eg, Intravenous Immunoglobulin (IVIG), routine systemic corticosteroids) is prohibited during the study. The use of antifibrinolytic agents or medications known to influence platelet function (eg, aspirin or certain non-steroidal anti-inflammatory drugs) within 5 days before initial study drug administration through Day 365 is prohibited. 5.7.2. Treatment(s) for Acute Bleeding Episodes If a subject experiences an acute bleeding episode at any point throughout the study, the subject is to be stabilized utilizing the subject’s standard hemostatic treatment regimen (which may include FVIII or FIX replacement therapy, or rFVIIa bypass agent therapy at approximately 90 μg/kg per dose). Pausing or withdrawal of treatment with investigational product is not required in the event of a breakthrough bleed, but may be considered at the discretion of the investigator. See Section 7.2.5 for additional information. 6. STUDY PROCEDURES 6.1. Screening All subjects participating in this study must sign the B7841003 informed consent or assent document (and parental consent must be completed, where required). The investigator (or an appropriate delegate at the investigator site) will obtain informed consent or assent from each subject in accordance with the procedures described in the Subject Information and Consent section (Section 12.3). B 7 8 4 1 0 0 3, i nf or m e d c o n s e nt pr o c e d ur e s will o c c ur at t h e D a y 1 vi sit. S cr e e ni n g a cti viti e s f or t h e s e s u bj e ct s, f oll o wi n g i nf or m e d c o n s e nt, will c o n si st of u si n g r e s ult s fr o m t h e fi n al vi sit of st u d y B 7 8 4 1 0 0 2 t o c o nfir m t h at n o n e of t h e B 7 8 4 1 0 0 3 st u d y e x cl u si o n crit eri a (S e cti o n 4. 2 ) h a v e b e e n m et. M e di c al hi st or y d at a f or s u bj e ct s fr o m st u d y B 7 8 4 1 0 0 2 will al s o b e u s e d f or s u bj e ct s e nr olli n g i nt o B 7 8 4 1 0 0 3. R e s ol v e d A E s fr o m B 7 8 4 1 0 0 2 m a y b e e nt er e d a s a d diti o n al m e di c al hi st or y , w h er e a p pli c a bl e. F or s u bj e ct s w h o h a v e c o m pl et e d p arti ci p ati o n i n st u d y B 7 8 4 1 0 0 2 m or e t h a n 3 0 d a y s pri or t o t h e D a y 1 vi sit i n st u d y B 7 8 4 1 0 0 3, a n d f or s u bj e ct s e nr oll e d d e n o v o i nt o st u d y B 7 8 4 1 0 0 3, t h e f oll o wi n g s cr e e ni n g a cti viti e s will a p pl y: T h e f oll o wi n g pr o c e d ur e s will b e c o m pl et e d d uri n g S cr e e ni n g:  O bt ai n writt e n i nf or m e d c o n s e nt.  R e vi e w I n cl u si o n a n d E x cl u si o n crit eri a.  O bt ai n c o m pl et e m e di c ati o n hi st or y of all pr e s cri pti o n or n o n pr e s cri pti o n dr u g s, a n d d i et ar y a n d h er b al s u p pl e m e nt s t a k e n si n c e t h e st art of S cr e e ni n g.  C oll e ct w ei g ht.  Pr o vi d e i n str u cti o n s r e g ar di n g st u d y c o ntr a c e pti o n r e q uir e m e nt s.  O bt ai n p ul s e r at e, r e s pir at or y r at e, or al t e m p er at ur e, a n d s u pi n e bl o o d pr e s s ur e.  C o n d u ct f ull p h y si c al e x a m i n ati o n ( P E). O n a n d aft er D a y 1 a n d at t h e di s cr eti o n of t h e i n v e sti g at or, li mit e d p h ysi c al e x a mi n ati o n s b a s e d o n si g n s a n d s y m pt o m s will b e p erf or m e d, if cli ni c all y i n di c at e d, t o a s s e s s c h a n g e s fr o m b a s eli n e/ pr e vi o u s vi sit s of a n y o n g oi n g sy m pt o m s.  C CI  F oll o wi n g at l e a st a 4 -h o ur f a st c oll e ct bl o o d a n d uri n e s p e ci m e n s f or t h e f oll o wi n g f or s hi p me nt t o t h e st u d y c e ntr al l a b or at or y :  Uri n al y si s;  S er u m c h e mi str y ;  H e m at ol o g y . The following additional screening procedures apply to de novo subjects who did not participate in study B7841002. • For adolescent subjects, obtain assent (and parental consent, where required). • Collect demography, height and weight. • Obtain medical history, including hemophilia history and inhibitor history, and collect the number of bleeding episodes over the past 6 months. • Review use of FVIII or FIX replacement therapy, or bypass agent therapy, to ensure subject meets washout criteria prior to Screening. • Collect blood specimens for the following for analysis at a local laboratory, if necessary: • Factor VIII or Factor IX inhibitor (this test is only required for subjects with a hemophilia history of inhibitors). Inhibitor test results from up to 6 months prior to Day 1 may be used to meet this requirement. • Following at least a 4-hour fast (and at least a 12-hour fast prior to lipid panel, collect blood and urine specimens for the following for shipment to the study central laboratory: • FVIII and FIX activity; • CD4 cell count; • Prothrombin 20210 mutation testing; • Factor V Leiden mutation testing; • Lipid panel; • Protein C activity/Protein S level; • Fibrinogen; • Serology (HBs Ag, HBc Ab, HCV Ab, and HIV). • Collect single 12-lead electrocardiogram (ECG). If ECG is abnormal, collect triplicate ECG. pr o c e d ur e s a n d i s r e- s cr e e ni n g i nt o t h e st u d y , wit h t h e e x c epti o n of t h e f oll o wi n g l a b s r el at e d t o g e n eti c m ut ati o n s cr e e ni n g C CI s a m pl e s:  Pr ot hr o m bi n 2 0 2 1 0 m ut ati o n t e sti n g.  F a ct or V L ei d e n m ut ati o n t e sti n g. C CI  F VIII a n d FI X a cti vit y . T o pr e p ar e f or st u d y p arti ci p ati o n, s u bj e ct s w ill b e i n str u ct e d o n t h e u s e of t h e Li f e styl e R e q uir e m e nt s a n d C o n c o mit a nt Tr e at m e nt( s) s e cti o n s of t h e pr ot o c ol. 6. 2. St u d y P e ri o d F or t h e st u d y p eri o d d e s cri b e d b el o w, w h e n m ulti pl e pr o c e d ur e s ar e s c h e d ul e d at t h e s a m e ti m e p oi nt( s) r el ati v e t o d o si n g, t h e f oll o wi n g c hr o n ol o g y of e v e nt s s h o ul d b e a d h er e d t o, w h er e p o s si bl e.  Bl o o d pr e s s ur e/ p ul s e r at e: pri or t o bl o o d s p e ci m e n c oll e cti o n. C CI  Ot h er pr o c e d ur e s ( e g, tr ai ni n g s u bj e ct o n s elf -a d mi ni str ati o n, di ar y c o m pli a n c e). W h e n a n I V c at h et er i s utili z e d f or bl o o d s a m pl e c oll e cti o n s, E C G s a n d vit al si g n s ( p ul s e r at e, r e s pir at or y r at e, bl o o d pre s s ur e a n d or al t e m p er at ur e) a s s e s s m e nt s s h o ul d b e c oll e ct e d pri or t o t h e i n s erti o n of t h e c at h et er. 6. 2. 1. D a y 1 Vi sit [ + 1 d a y] T h e D a y 1 vi sit f or B 7 8 4 1 0 0 3 m a y o c c ur o n t h e s a m e d a y ( s a m e vi sit t o t h e cli ni c) a s t h e B 7 8 4 1 0 0 2 D a y 8 5 or D a y 1 1 3 vi sit. All D a y 1 ( or B 7 8 4 1 0 0 2 D a y 8 5 or D a y 1 1 3) bl o o d dr a w s m u st b e d o n e pri or t o a d mi ni str ati o n of I P. P ri o r t o d o si n g o n D a y 1 t h e f oll o wi n g pr o c e d ur e s will b e c o m pl et e d:  F o r s u bj e ct s w h o c o m pl et e d st u d y B 7 8 4 1 0 0 2, o bt ai n w ritt e n i nf o r m e d c o n s e nt.  A s s e s s b a s eli n e s y m pt o m s/ A E s.  R e vi e w c h a n g e s i n s u bj e ct’ s c o n c o mit a nt tr e at m e nt i nf or m ati o n.  R e vi e w u s e of F VIII or FI X r e pl a c e m e nt t h er a p y, or b y p a s s a g e nt t h er a p y, t o e n s ur e a n y d e n o v o s u bj e ct m e et s w a s h o ut crit eri a pri or t o D a y 1 .  R e vi e w c h a n g e s i n t h e s u bj e ct’ s m e di c al hi st or y i n cl u di n g m e di c ati o n.  C oll e ct i nf or m ati o n o n n e w bl e e di n g e pi s o d e s.  R e vi e w I n cl u si o n a n d E x cl u si o n crit eri a f or a n y d e n o v o s u bj e ct.  C o n d u ct a li mit e d p h y si c al e x a mi n ati o n at t h e di s cr eti o n of t h e i n v e sti g at or, if cli ni c all y i n di c at e d, t o a s s e s s c h a ng e s of a n y o n g oi n g s y m pt o m s.  C o nfir m pr o p er c o ntr a c e pti o n i s b ei n g u s e d.  O bt ai n p ul s e r at e, r e s pir at or y r at e, or al t e m p er at ur e, a n d s u pi n e bl o o d pr e s s ur e.  C oll e ct bl o o d a n d uri n e s p e ci m e n s f or t h e f oll o wi n g f or s hi p m e nt t o t h e st u d y c e ntr al l a b or at or y:  Uri n al y si s;  S er u m c h e mi str y ;  H e m at ol o g y wit h diff er e nti al p a n el;  F VIII a n d FI X a cti vit y ; C CI  P T; C CI  F or d e n o v o s u bj e ct s, t h e f oll o wi n g a cti viti e s ar e al s o r e q uir e d pri or t o d o si n g:  C oll e ct bl o o d a n d uri n e s p e ci m e n s f or t h e f oll o wi n g f or s hi p m e nt t o t h e st u d y c e ntr al l a b or at or y :  Fi bri n o g e n;  C ar di a c tr o p o ni n I.  C oll e ct tri pli c at e 1 2 -l e a d E C G.  Tr e at m e nt a s si g n m e nt a n y ti m e pri or t o d o si n g o n c e s u bj e ct h a s m et all eli gi bilit y crit eri a.  Aft er all pr e -d o s e pr o c e d ur e s h a v e b e e n c o m pl et e d, a d mi ni st er t h e i n v e sti g ati o n al pr o d u ct ( s e e S T U D Y T R E A T M E N T S a n d A d mi ni str ati o n S e cti o n s). Aft e r d o si n g , t h e f oll o wi n g pr o c e d ur e s will b e c o m pl et e d:  M o nit or i nf u si o n/i nj e cti o n sit e r e a cti o n s.  A s s e s s s y m pt o m s b y s p o nt a n e o u s r e p orti n g of a d v er s e e v e nt s a n d b y a s ki n g t h e s u bj e ct s t o r e s p o n d t o a n o n -l e a di n g q u e sti o n s u c h a s “ H o w d o y o u f e el ? ”  I s s u e s u bj e ct di ar y a n d pr o vi d e tr ai ni n g wit h r e s p e ct t o c o m pl eti n g t h e di ar y i n cl u di n g ti mi n g a n d n at ur e of i nf or m ati o n t o b e e nt er e d. 6. 2. 2. D a y 2 [ 1 d a y], D a y 4 [ 1 d a y], D a y 8 [ 2 d a y s], D a y 1 5 [ 2 d a y s], D a y 2 2 [  2 d a y s] a n d D a y 2 9 [ 2 d a y s] – C CI T r e at m e nt Vi sit s f o r D e N o v o S u bj e ct s T h e f oll o wi n g pr o c e d ur e s will b e c o m pl et e d at t h e vi sit s a b o v e f or d e n o v o s u bj e ct s o nl y :  O bt ai n i nf or m ati o n r e g ar di n g t h e u s e of c o n c o mit a nt tr e at m e nt a n d t h e o c c urr e n c e of a d v er s e e v e nt s.  C oll e ct i nf or m ati o n o n n e w bl e e di n g e pi s o d e s.  C o n d u ct a li mit e d p h y si c al e x a mi n ati o n at t h e di s cr eti o n of t h e i n v e sti g at or, if cli ni c all y i n di c at e d, t o a s s e s s c h a n g e s fr o m b a s elin e/ pr e vi o u s vi sit s of a n y o n g oi n g s ym pt o m s.  C o nfir m pr o p er c o ntr a c e pti o n i s b ei n g u s e d.  C oll e ct bl o o d s p e ci m e n s f or t h e f oll o wi n g f or s hi p m e nt t o t h e st u d y c e ntr al l a b or at or y ( n ot e t h at D a y 2 9 bl o o d s p e ci m e n s ar e i n a d diti o n t o D a y 2 9 a cti viti e s p erf or m e d o n all st u d y s u bj e ct s p er S e cti o n 6. 2. 3 ): C CI  S er u m c h e mi str y ( D a y 8, 1 5, 2 2, 2 9);  H e m at ol o g y wit h diff er e nti al p a n el ( D a y 8, 1 5, 2 2, 2 9);  P T ( D a y 8, 1 5, 2 2, 2 9); C CI  C ar di a c tr o p o ni n I ( D a y 8, 1 5, 2 2, 2 9).  O bt ai n p ul s e r at e, r e s pir at or y r at e, or al t e m p er at ur e, a n d s u pi n e bl o o d pr e s s ur e. ( D a y 2 9).  C oll e ct si n gl e 1 2 -l e a d E C G. If E C G i s a b n or m al, c oll e ct tri pli c at e E C G ( D a y 2 9).  D a y 8, D a y 1 5 a n d D a y 2 2 - Aft er all pr e -d o s e pr o c e d ur e s h a v e b e e n c o m pl et e d, a d mi ni st er t h e i n v e sti g ati o n al pr o d u ct ( s e e S T U D Y T R E A T M E N T S a n d A d mi ni str ati o n S e cti o n s).  M o nit or i nj e cti o n sit e r e a cti o n s.  C oll e ct t h e s u bj e ct’ s di ar y a n d r e vi e w wit h t h e s u bj e ct/ c ar e gi v er, i n cl u di n g i nf or m ati o n a b o ut st u d y c o m pli a n c e, i n v e sti g ati o n al pr o d u ct i nf u si o n s, bl e e di n g a s s e s s m e nt s (i n cl u di n g sit e a n d tr a u m ati c/ s p o nt a n e o u s) a n d i nj e cti o n sit e r e a cti o n s. Di s p e n s e n e w s u bj e ct di ar y. 6. 2. 3. D a y 2 9 [ 2 d a y s], D a y 5 7 [  5 d a y s], D a y 8 5 [  5 d a y s], D a y 1 1 3 [  7 d a y s], D a y 1 4 1 [  7 d a y s], D a y 1 6 9 [  7 d a y s], D a y 2 2 5 [  7 d a y s], D a y 2 5 3 [  7 d a y s], D a y 2 8 1 [ 7 d a y s], D a y 3 0 9 [  7 d a y s], D a y 3 3 7 [  7 d a y s], a n d D a y 3 6 5 [  7 d a y s] Vi sit s T h e f oll o wi n g pr o c e d ur e s will b e c o m pl et e d:  O bt ai n i nf or m ati o n r e g ar di n g t h e u s e of c o n c o mit a nt tr e at m e nt a n d t h e o c c urr e n c e of a d v er s e e v e nt s.  C oll e ct i nf or m ati o n o n n e w bl e e di n g e pi s o d e s.  C o n d u ct a li mit e d p h y si c al e x a mi n ati o n at t h e di s cr eti o n of t h e i n v e sti g at or, if cli ni c all y i n di c at e d, t o a s s e s s c h a n g e s fr o m b a s eli n e/ pr e vi o u s vi sit s of a n y o n g oi n g s ym pt o m s.  C o nfir m pr o p er c o ntr a c e p ti o n i s b ei n g u s e d.  O bt ai n p ul s e r at e, r e s pir at or y r at e, or al t e m p er at ur e, a n d s u pi n e bl o o d pr e s s ur e.  lC aolbl oercta t bolr oy.o d s p e ci m e n s f or t h e f oll o wi n g f or s hi p m e nt t o t h e st u d y c e ntr al  D e n o v o s u bj e ct s o nl y :  S er u m c h e mi str y ( D a y 5 7);  H e m at ol o g y ( D a y 5 7).  C oll e ct t h e s u bj e ct’ s di ar y a n d r e vi e w wit h t h e s u bj e ct/ c ar e gi v er, i n cl u di n g i nf or m ati o n a b o ut st u d y c o m pli a n c e, i n v e sti g ati o n al pr o d u ct i nf u si o n s, bl e e di n g a s s e s s m e nt s (i n cl u di n g sit e a n d tr a u m ati c/ s p o nt a n e o u s) a n d i nj e cti o n sit e r e a cti o n s. Di s p e n s e n e w s u bj e ct di ar y .  M o nit or i nf u si o n/i nj e cti o n sit e r e a cti o n s.  D a y 8 5 [  7 d a y s ], D a y 1 6 9 [  7 d a y s], D a y 2 5 3 [  7 d a y s], a n d D a y 3 6 5 [  7 d a y s] - C oll e ct bl o o d a n d uri n e s p e ci m e n s f or t h e f oll o wi n g f or s hi p m e nt t o t h e st u d y c e ntr al l a b or at or y:  Uri n al y si s;  S e r u m c h e mi str y;  H e m at ol o g y wit h diff er e nti al p a n el;  F VIII a n d FI X a cti vit y ; C CI  P T; C CI  Aft er all pr e -d o s e pr o c e d ur e s h a v e b e e n c o m pl et e d, a d mi ni st er t h e i n v e sti g ati o n al pr o d u ct ( s e e S T U D Y T R E A T M E N T S a n d A d mi ni str ati o n S e cti o n s).  Di s p e n s e i n v e sti g ati o n al pr o d u ct t o s elf -a d mi ni str ati o n at h o m e (if a p pli c a bl e).  D a y 3 3 7 i s t h e fi n al vi sit f or di s p e n si n g i n v e sti g ati o n al pr o d u ct t o t h e s u bj e ct f or • No IP will be administered or dispensed on Day 365. 6.2.4. Day 393 [±±7 days] – End of Study Visit The following procedures will be completed: • Obtain information regarding the use of concomitant treatment and the occurrence of adverse events. • Collect information on new bleeding episodes. • Monitor infusion/injection site reactions. • Assess symptoms by spontaneous reporting of adverse events and by asking the subjects to respond to a non-leading question such as “How do you feel?” • Conduct a full physical examination. • Collect the subject’s diary and review with the subject/caregiver, including information about study compliance, investigational product infusions, bleeding assessments (including site and traumatic/spontaneous) and injection site reactions. • Confirm proper contraception is being used. • Collect weight. • Obtain pulse rate, respiratory rate, oral temperature, and supine blood pressure. 6.2.5. Follow-up Contact Follow-up contact will be completed at least 28 calendar days, and up to 35 calendar days after the last administration of the investigational product to capture any potential adverse events (see the Time Period for Collecting AE/SAE Information section) and to confirm appropriate contraception usage (see the Contraception section). Contact with the subject may be done via a phone call. 6.3. Subject Withdrawal or Early Termination Withdrawal of consent: Subjects who request to discontinue receipt of study treatment will remain in the study and must continue to be followed for protocol specified follow-up procedures. The only exception to this is when a subject specifically withdraws consent for any further contact with him or her or persons previously authorized by the subject to provide this information. Subjects should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is only from further receipt of investigational product or also from study procedures and/or post-treatment study follow-up, and entered on the appropriate case report form (CRF) page. In the event that vital status (whether the subject is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law. Lost to follow-up: All reasonable efforts must be made to locate subjects to determine and report their ongoing status. This includes follow-up with persons authorized by the subject as noted above. Lost to follow-up is defined by the inability to reach the subject after a minimum of 2 documented phone calls, faxes, or e-mails as well as lack of response by the subject to 1 registered mail letter. All attempts should be documented in the subject’s medical records. If it is determined that the subject has died, the site will use locally permissible methods to obtain the date and cause of death. If the investigator’s use of a third-party representative to assist in the follow-up portion of the study has been included in the subject’s informed consent, then the investigator may use a sponsor-retained third-party representative to assist site staff with obtaining the subject’s contact information or other public vital status data necessary to complete the follow-up portion of the study. The site staff and representative will consult publicly available sources, such as public health registries and databases, in order to obtain updated contact information. If, after all attempts, the subject remains lost to follow-up, then the last-known-alive date as determined by the investigator should be reported and documented in the subject’s medical records. Subjects may withdraw from the study at any time at their own request, or they may be withdrawn at any time at the discretion of the investigator or sponsor for safety (see also the Withdrawal From the Study Due to Adverse Events section) or behavioral reasons, or the inability of the subject to comply with the protocol-required schedule of study visits or procedures at a given study site. If a subject does not return for a scheduled visit, every effort should be made to contact the subject. In any circumstance, every effort should be made to document subject outcome, if possible. The investigator should inquire about the reason for withdrawal, request that the subject return all unused investigational product, request that the subject return for a final visit, if applicable, and follow up with the subject regarding any unresolved adverse events (AEs). If the subject withdraws from the study, and also withdraws consent for disclosure of future information, no further evaluations should be performed, and no additional data should be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent. Subjects who withdraw from the study for reasons other than safety may be replaced at the discretion of the sponsor. 7. ASSESSMENTS Every effort should be made to ensure that the protocol-required tests and procedures are completed as described. However, it is anticipated that from time to time there may be circumstances outside of the control of the investigator that may make it unfeasible to perform the test. In these cases the investigator will take all steps necessary to ensure the safety and well-being of the subject. When a protocol-required test cannot be performed, the investigator will document the reason for this and any corrective and preventive actions that he or she has taken to ensure that normal processes are adhered to as soon as possible. The study team will be informed of these incidents in a timely manner. For samples being collected and shipped, detailed collection, processing, storage, and shipment instructions and contact information will be provided to the investigator site prior to initiation of the study. 7.1. Safety 7.1.1. Laboratory Tests The following safety laboratory tests will be performed at times defined in the Schedule of Activities section of this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by the clinical laboratory; or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical labs may be obtained at any time during the study to assess any perceived safety concerns. H e m at ol o g y d C h e mist r y U ri n al ysis Ot h e r H e m o gl o bi n B U N/ ur e a a n d Cr e ati ni n e p H F a ct or V L ei d e n m ut ati o n b H e m at o crit Gl u c os e (f asti n g) Gl u c os e ( q u al) Pr ot hr o m bi n 2 0 2 1 0 M ut ati o n b R B C c o u nt C al ci u m Pr ot ei n ( q u al) H Bs A g b Pl at el et c o u nt S o di u m Bl o o d ( q u al) T ot al H B c A b b W B C c o u nt P ot assi u m K et o n es H C V A b b T ot al n e utr o p hils C hl ori d e Nitrit es HI V b ( A bs) T ot al C O ( Bi c ar b o n at e) L e u k o c yt e est er as e A nti -t hr o mbi n III 2 E osi n o p hils ( A bs) A S T, A L T Ur o bil i n o g e n Pr ot ei n C a cti vit y b M o n o c yt es ( A bs) T ot al bilir u bi n Uri n e bilir u bi n Pr ot ei n S l e v el b B as o p hils ( A bs) Al k ali n e p h os p h at as e Mi cr os c o p y a P T/I N R L y m p h o c yt es ( A bs) Uri c a ci d C CI Al b u mi n T ot al pr ot ei n Fi bri n o g e n C ar di a c Tr o p o ni n I (f or d e n o v o s u bj e cts o nl y) F a ct or VIII c F a ct or I X c F a ct or VIII a n d F a ct or I X i n hi bit ore Li pi d pr ofil e b C D 4 c ell c o u nt b A d diti o n al T ests ( N e e d e d f or H y’s l a w) A S T, A L T (r e p e at) T ot al bilir u bi n (r e p e at) Al b u mi n (r e p e at) Al k ali n e p h os p h at as e (r e p e at) Dir e ct bilir u bi n I n dir e ct bilir u bi n Cr e ati n e ki n as e G G T P T/I N R a. O nl y if uri n e di psti c k is p ositi v e f or bl o o d, pr ot ei n, nitrit es or l e u k o c yt e est er as e. b. F or d e n o v o s u bj e cts at S cr e e ni n g o nl y. c. F or d e n o v o s u bj e cts at At S cr e e ni n g a n d D a y 1 o nl y. d. Diff er e nti al h e m at ol o g y p a n el r e q uir e d a t D a ys 1, 8 5, 1 6 9, 2 5 3 a n d 3 6 5 . e. O nl y At S cr e e ni n g a n d o nl y f or s u bj e cts w it h h e m o p hili a hist or y of i n hi bit ors, if n e c ess ar y. I n hi bit or t est r es ults fr o m u p t o 6 m o nt hs pri or t o D a y 1 m a y b e us e d t o m e et r e q uir e m e nt. F VIII a n d FI X i n hi bit or l e v els m ust b e d et er mi n e d b y a l o c al l a b or at or y. A p ositi v e i n hi bit or t est r es ult will b e a b o v e t h e u p p er li mit of n or m al f or t h e ass a y. C CI 7.1.2. Physical Examinations Physical examinations may be conducted by a physician, trained physician’s assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination will include head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination will be focused on general appearance, the respiratory and cardiovascular systems, as well as towards subject reported symptoms. For measuring weight, a scale with appropriate range and resolution is used and must be placed on a stable, flat surface. Subjects must remove shoes, bulky layers of clothing, and jackets so that only light clothing remains. They must also remove the contents of their pockets and remain still during measurement of weight. 7.1.3. Blood Pressure and Pulse Rate Blood pressure and pulse rate will be measured at times specified in the Schedule of Activities. Additional collection times, or changes to collection times of blood pressure and pulse rate will be permitted, as necessary, to ensure appropriate collection of safety data. Supine blood pressure will be measured with the subject’s arm supported at the level of the heart, and recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm (preferably the dominant arm) should be used throughout the study. Subjects should be instructed not to speak during measurements. Where possible, the same properly sized and calibrated blood pressure cuff will be used to measure blood pressure each time. The use of an automated device for measuring blood pressure (BP) and pulse rate is acceptable, although, when done manually, pulse rate will be measured in the brachial/radial artery for at least 30 seconds. When the timing of these measurements coincides with a blood collection, blood pressure and pulse rate should be obtained prior to the nominal time of the blood collection. 7.1.4. Respiratory Rate Respiratory rate should be measured after approximately 5 minutes rest in supine position by observing and counting the respirations of the subject for 30 seconds and multiplied by 2. When blood pressure is to be taken at the same time, measurement should be done during the 5 minutes of rest and before blood pressure measurement. 7.1.5. Temperature Temperature will be measured orally. No eating, drinking or smoking is allowed for 15 minutes prior to the measurement. 7.1.6. Electrocardiogram ECGs should be collected at times specified in the Schedule of Activities. All scheduled ECGs should be performed after the subject has rested quietly for at least 10 minutes in a supine position. Triplicate 12-lead ECGs (Day 1 only) will be obtained approximately 2-4 minutes apart; the average of the triplicate ECG measurements collected at each nominal time point on Day 1 will serve as each subject’s baseline QTcF value. To ensure safety of the subjects, a qualified individual at the investigator site will make comparisons to baseline measurements. If the QTcF interval is increased by ≥45 msec from the baseline, or an absolute QTcF value is ≥500 msec for any scheduled ECG, then 2 additional ECGs will be collected, approximately 2-4 minutes apart, to confirm the original measurement. If either of the QTcF values from these repeated ECGs remains above the threshold value (≥45 msec from the baseline; or is ≥500 msec), then a single ECG must be repeated at least hourly until QTcF values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement. If the average of QTcF values from the triplicate measurements remains above the threshold value (≥45 msec from the baseline; or is ≥500 msec), then a single ECG must be repeated at least hourly until QTcF values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement. If QTcF values remain ≥500 msec (or ≥45 msec from the baseline) for greater than 4 hours (or sooner at the discretion of the investigator); or QTcF intervals get progressively longer, the subject should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF intervals do not return to less than 500 msec (or to <45 msec above the baseline) after 8 hours of monitoring (or sooner at the discretion of the investigator). In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead placement as contributing to the ECG abnormality. It is important that leads are placed in the same positions each time in order to achieve precise ECG recordings. If a machine-read QTcF value is prolonged, as defined above, repeat measurements may not be necessary if a qualified physician’s interpretation determines that the QTcF values are in the acceptable range. 7.1.7. Injection Site Reactions Injection site reactions will be assessed according to the Schedule of Activities. Injection site reactions may include but are not limited to: erythema, induration, ecchymosis, pain and pruritus. The size and severity of injection site reactions will be assessed and documented. If deemed appropriate by the investigator, a consultation with a dermatologist will be performed. Documentation may include a dermatologist report, clinic notes and photographs. 7.2. Efficacy 7.2.1. Hemophilic Bleeding Episodes During this study, the investigator (or qualified designee) will review the subject diary with the subject, and inquire about and record AEs, concomitant treatments, bleeding episodes (including location and etiology – traumatic or spontaneous) and any hemostatic treatments (including intravenous treatments with coagulation factor products). Hemostatic therapy that is administered to treat bleeding episodes during the Screening period and during the study through the final study visit will be documented as concomitant treatment. Subject diary review will include any bleeding episodes treated with hemostatic agents. Bleeding episodes requiring treatment with intravenous coagulation factor products will count toward the determination of bleeding episode frequency during the period of treatment with PF-06741086. Subject assessment(s) will be captured on the subject diary and reviewed by the investigator at study visits. One assessment per infusion will be required. 7.2.2. Bleeding Occurrences of bleeding episodes treated with hemostatic agent(s) will be obtained from subject diaries and medical records. Where relevant, investigators (or designee) and monitors will ensure that there is consistency between the subject’s medical record and/or subject diaries and the CRFs. Bleeding episodes will not be reported as AEs unless associated with a serious adverse event, although the concomitant events associated with a bleed may be reported as an AE if appropriate (eg, a fracture, pain - see Section 8.2.3 below for guidance on hemophilia related events). Both spontaneous bleeding episodes and traumatic bleeding episodes will be collected. Only bleeding episodes that are considered serious and meet the SAE criteria should be listed on the AE CRF page. When bleeding episodes that meet the SAE criteria are recorded on the AE CRF, the location (site) of the bleed and the etiologic classification as spontaneous or traumatic should be included (as described in Section 7.2.1 and Section 7.2.3). The subject diary or medical record will serve as the source document for bleeding episodes during the study. Investigators (or designee) and/or monitors will review the subject’s diary/medical records to assist in classification if necessary. 7.2.3. Types of Bleeding For the purposes of this study, a bleed treated with a hemostatic agent will be classified as either spontaneous or traumatic. The criteria for spontaneous and traumatic bleeds are described below. • Spontaneous Bleeding Episodes: Bleeding episodes should be classified as spontaneous if a subject records a bleeding event when there is no known contributing factor such as definite trauma, antecedent “strenuous” activity, or “overuse”. The determination of “strenuous” or “overuse” is at the discretion of the subject/caregiver/investigator. For example, if a subject were to wake up in the morning and note he was bleeding, a “spontaneous” bleed would be recorded. Target joints can have spontaneous bleeding episodes.  Tifr aa us umbajtei cct rBle ec eordid sn ga bElpeies doidnegs :e vBel nete dwi hn eg n etphi seroed iess as hkonuol dw nb eo rc lparsessifui emde da sc tor naturi mb auttiicn g f a ct or/r e a s o n f or t h e bl e e d. F or e x a m ple, if a s u bj e ct w er e t o e x er ci s e “ str e n u o u sl y ” a n d t h e n h a v e a bl e e d i n t h e a b s e n c e of a n y o b vi o u s i nj ur y, t h e bl e e d w o ul d b e r e c or d e d a s a tr a u m ati c bl e e d. T ar g et j oi nt bl e e di n g e pi s o d e s c a n b e tr a u m ati c if a k n o w n a cti o n l e d t o bl e e di n g i nt o t h e j oi nt. 7. 2. 4. L o c ati o n of Bl e e d s F or t h e p ur p o s e s of t hi s st u d y , w h e n s u bj e ct s r e p ort a bl e e d tr e at e d wit h h e m o st ati c t h er a py, t h e l o c ati o n of t h e bl e e d s h o ul d b e r e c or d e d i n t h e s u bj e ct di ar y or m e di c al r e c or d. Bl e e d s will b e r e p ort e d a s o c c urri n g i n 1 of t h e f oll o wi n g l o c ati o n s: j oi nt, m u s cl e/ s oft ti s s u e, or ot h er. E a c h i n di vi d u al l o c ati o n of m ulti pl e - sit e bl e e d s will b e r e p ort e d. F or j oi nt bl e e d s, t h e s p e cifi c j oi nt will b e r e p ort e d. P ar a m et er s t o i d e ntif y j oi nt bl e e d s i n cl u d e: p ai n o n j oi nt m oti o n, li mit ati o n of m oti o n, a n d vi si bl e s w elli n g of j oi nt. 7. 2. 5. T r e at m e nt of Bl e e di n g E pi s o d e s Bl e e di n g e pi s o d e s t h at o c c ur d uri n g t hi s st u d y m a y b e tr e at e d ( o n-d e m a n d) wit h h e m o st ati c t h er a py ( e g, i ntr a v e n o u s c o a g ul ati o n f a ct or pr o d u ct s or r F VII a b y p a s s a g e nt t h er a p y at a p pr o xi m at el y 9 0 µ g/ k g, a d mi ni st er e d at i nt er v al s  2 h o ur s ) a s d e e m e d a p pr o pri at e by t h e i n v e sti g at or. T h e s p e cifi c tr e at m e nt wit h h e m o st ati c t h er a py i s at t h e di s cr eti o n of t h e s u bj e ct/ c ar e gi v er/i n v e sti g at or, b ut all d o s e s of h e m o st ati c t h er a p y t a k e n aft er si g ni n g of i nf or m e d c o n s e nt will b e d o c u m e nt e d a s c o n c o mit a nt m e di c ati o n s or c o n c o mit a nt tr e at m e nt s. If a s u bj e ct e x p eri e n c e s a bl e e di n g e pi s o d e d uri n g t h e w a s h o ut p eri o d pr e c e di n g s cr e e ni n g l a b or at or y a s s e s s m e nt s, t h e s u bj e ct i s t o b e st a bili z e d utili zi n g t h e s u bj e ct’ s u s u al h e m o st ati c tr e at m e nt r e gi m e n. O n c e t h e bl e e di n g e pi s o d e h a s b e e n s u c c e s sf ully tr e at e d a n e w w a s h o ut p eri o d s h o ul d b e c o m pl et e d pri or t o o bt ai ni n g t h e s cr e e ni n g l a b or at or y t e st s. If a s u bj e ct e x p eri e n c e s a bl e e di n g e pi s o d e d uri n g t h e w a s h o ut p eri o d pr e c e di n g t h e i niti al a d mi ni str ati o n of P F -0 6 7 4 1 0 8 6 t h e s u bj e ct i s t o b e st a bili z e d utili zi n g t h e s u bj e ct’ s u s u al h e m o st ati c tr e at m e nt r e gi m e n a n d a n e w w a s h o ut p eri o d s h o ul d b e i m pl e m e nt e d. O n c e tr e at m e nt of t h e bl e e di n g e pi s o d e wit h h e m o st atic a g e nt s h a s b e e n c o m pl et e d a n e w w a s h o ut p eri o d s h o ul d b e i niti at e d i n a nti ci p ati o n of t h e i niti al tr e at m e nt wit h P F -0 6 7 4 1 0 8 6. C CI    7. 8. Bl o o d V ol u m e T h e t ot al bl o o d s a m pli n g v ol u m e f or d e n o v o s u bj e ct s i n t hi s st u d y i s a m a xi m u m of a p pr o xi m at el y 2 5 4 m L ( b a s e d o n S cr e e ni n g t hr o u g h D a y 1 9 7 ). S u bj e ct s c o nti n ui n g fr o m B 7 8 4 1 0 0 2 will h a v e a n a p pr o xi m at e m a xi m u m of 1 2 5 m L dr a w n d uri n g t h e st u d y . T h e t a bl e b el o w r efl e ct s a p pr o xi m at e s a m pl e v ol u m e s n e e d e d f or e a c h m e a s ur e d e n d p oi nt. T h e a ct u al c oll e cti o n ti m e s of bl o o d s a m pli n g m a y c h a n g e, b ut t h e a p pr o xi m at e t ot al bl o o d v ol u m e c oll e ct e d s h o ul d n ot i n cr e a s e. A d diti o n al bl o o d s a m pl e s m a y b e t a k e n f or s af ety a s s e s s m e nt s at ti m e s s p e cifi e d b y Pfi z er, pr o vi d e d t h e t ot al v ol u m e t a k e n d uri n g t h e st u d y d o e s n ot e x c e e d 5 5 0 m L d uri n g a ny p eri o d of 3 0 c o n s e c uti v e d a y s. S a m pl e T y p e S a m pl e N u m b e r of S a m pli n g Ti m e s c T ot al V ol u m e S cr e e ni n g St u d y F oll o w -U p V ol u m e ( mL) P eri o d ( mL) S af et y L a bs S er u m c h e mistr y ( wit h Li pi d pr ofil e a) 5 1 7 0 4 5 H e m at ol o g y d 3 1 7 0 2 7 Pr ot hr o m bi n 2 0 2 1 0 m ut ati o n 3 1 0 0 3 F a ct or V L ei d e n m ut ati o n t esti n g 3. 5 1 0 0 3. 5 P T/I N R, F a ct or VIII a n d F a ct or I X 4. 5 1 9 0 4 9. 5 a cti vit y, b Fi bri n o g e n, Pr ot ei n C, a Pr ot ei n S, a C CI [ Si n gl e c o m bi n e d s a m pl e] F a ct or VIII a n d F a ct or I X i n hi bit or a 4. 5 1 0 0 4. 5 C D 4 c ell c o u nt a bs ol ut e ( C D 4) a 5 1 0 0 5 S er ol o g y ( H Bs A g, H B c A b, H C V A b, 5 1 0 0 5 a n d HI V) C a r di a c T r o p o ni n I e 3 5 1 5 C CI a d e n o v o s u bj e cts at S cr e e ni n g o nl y. b d e n o v o s u bj e cts at S cr e e ni n g a n d D a y 1 o nl y. c t ot al sa m pl es r efl e cts a m o u nt r e q uir e d f or d e n o v o s u bj e cts ( w it h S cr e e ni n g a n d a d diti o n al visits d uri n g first m o nt h of tr e at m e nt); s u bj e cts c o nti n ui n g fr o m B 7 8 4 1 0 0 2 will h a v e l ess s a m pl es dr a w n a n d t h us l ess m a xi m u m bl o o d v ol u m e . d s cr e e ni n g s p e ci m e n o nl y f or n o v o s u bj e cts a n d f or s u bj e cts e nr olli n g > 3 0 d a ys f oll o wi n g d a y 8 5 or d a y 1 1 3 visit i n st u d y B 7 8 4 1 0 0 2, e at d a ys 1, 8, 1 5, 2 2 a n d 2 9 f or d e n o v o s u bj e cts o nl y. T a bl e 5. T ri g g e r e d R e q ui r e m e nt s C o n diti o n A cti o n  Pl at el et c o u nt < 7 5, 0 0 0/  L S u bj e ct s w h o ar e f o u n d t o h a v e o n e of t h e c o a g ul ati o n p at h w a y a b n or m aliti e s  Fi bri n o g e n l e v el < L L N d efi n e d b y t h e s e c orr e s p o n di n g l a b v al u e  H e m o gl o bi n l e v el < 1 0 g m/ d L crit eri a s h o ul d b e br o u g ht i nt o t h e cli ni c i m m e di at el y f or a n u n s c h e d ul e d vi sit a n d  P T/I N R  1. 2 5 ti m e s t h e U L N t h e r e s p e cti v e l a b or at or y t e st s h o ul d b e r e p e at e d. C CI 8. A D V E R S E E V E N T R E P O R T I N G 8. 1. R e q ui r e m e nt s T h e t a bl e b el o w s u m m ari z e s t h e r e q uir e m e nt s f or r e c or di n g s af et y e v e nt s o n t h e C R F a n d f or r e p orti n g s af et y e v e nt s o n t h e Cli ni c al Tri al (C T) S eri o u s A d v er s e E v e nt ( S A E) R e p ort F or m t o Pfi z er S af et y. T h e s e r e q uir e m e nt s ar e d eli n e at e d f or 3 t yp e s of e v e nt s: ( 1) S A E s; ( 2) n o n- s eri o u s a d v er s e e v e nt s ( A E s); a n d ( 3) e x p o s ur e t o t h e i n v e sti g ati o n al pr o d u ct u n d er st u d y d uri n g pr e g n a n c y or br e a stf ee di n g, a n d o c c u p ati o n al e x p o s ur e. S af et y E v e nt R e c o r d e d o n t h e C R F R e p o rt e d o n t h e C T S A E R e p o rt F o r m t o Pfi z e r S af et y Wit hi n 2 4 H o u r s of A w a r e n e s s S A E All All N o n -s eri o u s A E All N o n e E x p o s ur e t o t h e All (r e g ar dl e s s of w h et h er E x p o s ur e d uri n g pr e g n a n c y , i n v e sti g ati o n al pr o d u ct a s s o ci at e d wit h a n A E), e x p o s ur e vi a br e a stf e e di n g, u n d er st u d y d uri n g e x c e pt o c c u p ati o n al o c c u p ati o n al e x p o s ur e pr e g n a n c y or e x p o s u r e (r e g ar dl e s s of w h et h er br e a stf e e di n g, a n d a s s o ci at e d wit h a n A E) o c c u p ati o n al e x p o s ur e All o b s er v e d or v ol u nt e er e d e v e nt s r e g ar dl e s s of tr e at m e nt gr o u p or s u s p e ct e d c a u s al r el ati o n s hi p t o t h e i n v e sti g ati o n al pr o d u ct( s) will b e r e p ort e d a s d e s cri b e d i n t h e f oll o wi n g p ar a gr a p h s. Events listed in the table above that require reporting to Pfizer Safety on the CT SAE Report Form within 24 hours of awareness of the event by the investigator are to be reported regardless of whether the event is determined by the investigator to be related to an investigational product under study. In particular, if the SAE is fatal or life-threatening, notification to Pfizer Safety must be made immediately, irrespective of the extent of available event information. This time frame also applies to additional new (follow-up) information on previously forwarded reports. In the rare situation that the investigator does not become immediately aware of the occurrence of an event, the investigator must report the event within 24 hours after learning of it and document the time of his/her first awareness of the event. For each event, the investigator must pursue and obtain adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE (see the Serious Adverse Events section below). In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up information in an expedited fashion. This information is more detailed than that recorded on the CRF. In general, this will include a description of the event in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a subject death, a summary of available autopsy findings must be submitted as soon as possible to Pfizer Safety. Any pertinent additional information must be reported on the CT SAE Report Form; additional source documents (eg, medical records, CRF, laboratory data) are to be sent to Pfizer Safety ONLY upon request. As part of ongoing safety reviews conducted by the sponsor, any non-serious AE that is determined by the sponsor to be serious will be reported by the sponsor as an SAE. To assist in the determination of case seriousness, further information may be requested from the investigator to provide clarity and understanding of the event in the context of the clinical study. As noted in the Protocol-Specified Serious Adverse Events section, should an investigator judge one of the identified protocol-specified SAEs to have a causal relationship with the investigational product, the investigator must report the SAE to Pfizer Safety within 24 hours of investigator awareness. 8.1.1. Additional Details On Recording Adverse Events on the CRF All events detailed in the table above will be recorded on the AE page(s) of the CRF. It should be noted that the CT SAE Report Form for reporting of SAE information is not the same as the AE page of the CRF. When the same data are collected, the forms must be completed in a consistent manner. AEs should be recorded using concise medical terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information. 8.1.2. Eliciting Adverse Event Information The investigator is to record on the CRF all directly observed AEs and all AEs spontaneously reported by the study subject/parent(s)/legal guardian/legally acceptable representative. In addition, each study subject/parent(s)/legal guardian/legally acceptable representative will be questioned about the occurrence of AEs in a non-leading manner. 8.1.3. Withdrawal From the Study Due to Adverse Events (see also the Subject Withdrawal or Early Termination section) Withdrawal due to AEs should be distinguished from withdrawal due to other causes, according to the definition of AE noted below, and recorded on the CRF. When a subject withdraws from the study because of an SAE, the SAE must be recorded on the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the Requirements section above. 8.1.4. Time Period for Collecting AE/SAE Information The time period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each subject begins from the time the subject provides informed consent, which is obtained before the subject’s participation in the study (ie, before undergoing any study-related procedure and/or receiving investigational product), through and including a minimum of 28 calendar days; except as indicated below after the last administration of the investigational product. For subjects who are screen failures, the active collection period ends when screen failure status is determined. 8.1.4.1. Reporting SAEs to Pfizer Safety All SAEs occurring in a subject during the active collection period are reported to Pfizer Safety on the CT SAE Report Form. SAEs occurring in a subject after the active collection period has ended are reported to Pfizer Safety if the investigator becomes aware of them; at a minimum, all SAEs that the investigator believes have at least a reasonable possibility of being related to investigational product must be reported to Pfizer Safety. Follow up by the investigator continues throughout and after the active collection period and until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment. 8.1.4.2. Recording Non-serious AEs and SAEs on the CRF During the active collection period, both non-serious AEs and SAEs are recorded on the CRF. Follow-up by the investigator may be required until the event or its sequelae resolve or 8.1.5. Causality Assessment The investigator’s assessment of causality must be provided for all AEs (serious and non-serious); the investigator must record the causal relationship on the CRF, and report such an assessment in accordance with the SAE reporting requirements, if applicable. An investigator’s causality assessment is the determination of whether there exists a reasonable possibility that the investigational product caused or contributed to an AE; generally the facts (evidence) or arguments to suggest a causal relationship should be provided. If the investigator does not know whether or not the investigational product caused the event, then the event will be handled as “related to investigational product” for reporting purposes, as defined by the sponsor. If the investigator's causality assessment is “unknown but not related” to investigational product, this should be clearly documented on study records. In addition, if the investigator determines that an SAE is associated with study procedures, the investigator must record this causal relationship in the source documents and CRF, and report such an assessment in the dedicated section of the CT SAE Report Form and in accordance with the SAE reporting requirements. 8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities AE reporting, including suspected unexpected serious adverse reactions, will be carried out in accordance with applicable local regulations. 8.2. Definitions 8.2.1. Adverse Events An AE is any untoward medical occurrence in a study subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Examples of AEs include, but are not limited to: • Abnormal test findings; • Clinically significant signs and symptoms; • Changes in physical examination findings; • Hypersensitivity; • Progression/worsening of underlying disease; • Drug abuse; • Drug dependency. Additionally, AEs may include signs and symptoms resulting from: • Drug overdose; • Drug withdrawal; • Drug misuse; • Drug interactions; • Extravasation; • Exposure during pregnancy (EDP); • Exposure via breastfeeding; • Medication error; • Occupational exposure. 8.2.2. Abnormal Test Findings Abnormal objective test findings should be recorded as AEs when any of the following conditions are met: • Test result is associated with accompanying symptoms; and/or • Test result requires additional diagnostic testing or medical/surgical intervention; and/or • Test result leads to a change in study dosing (outside of any protocol-specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy; and/or • Test result is considered to be an AE by the investigator or sponsor. Merely repeating an abnormal test, in the absence of any of the above conditions, does not constitute an AE. Any abnormal test result that is determined to be an error does not require recording as an AE. 8.2.3. Hemophilia Events Hemophilia events are certain AEs that are likely to occur due to the subject’s hemophilia. For example, pain, swelling, or decreased range of motion due to a bleed may be an expected consequence of hemophilia (the bleeding episode itself is not reported as an AE, unless the bleeding episode meets the criteria for a Serious Adverse Event, see Section 8.2.4). Investigators should determine if an AE is expected because of the subject’s hemophilia. Bleeding or bruising, not due to the subject’s hemophilia, will be recorded as an AE, and not a hemophilia event. Hemophilia events that require hospitalization or meet other SAE criteria should be reported as SAEs. 8.2.4. Serious Adverse Events A serious adverse event is any untoward medical occurrence at any dose that: • Results in death; • Is life-threatening (immediate risk of death); • Requires inpatient hospitalization or prolongation of existing hospitalization; • Results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); • Results in congenital anomaly/birth defect. Or that is considered to be: • An important medical event. Medical and scientific judgment is exercised in determining whether an event is an important medical event. An important medical event may not be immediately life-threatening and/or result in death or hospitalization. However, if it is determined that the event may jeopardize the subject or may require intervention to prevent one of the other AE outcomes, the important medical event should be reported as serious. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse. Medical device complaints may meet the SAE reporting requirement criteria (see the Medical Device Complaint Reporting Requirements section). An incident is any malfunction (ie, the failure of a device to meet its performance specifications or to perform as intended; performance specifications include all claims made in the labeling for the device) that, directly or indirectly, might lead to or might have led to the death of a subject, or user, or of other persons, or to a serious deterioration in their state of health. A serious injury that can cause a serious deterioration in state of health can include: • A life-threatening illness, even if temporary in nature; • A permanent impairment of a body function or permanent damage to a body structure; • A condition necessitating medical or surgical intervention to prevent the above 2 bulleted items: • Examples: clinically relevant increase in the duration of a surgical procedure; a condition that requires hospitalization or significant prolongation of existing hospitalization. • Any indirect harm as a consequence of an incorrect diagnostic or in vitro diagnostic device test results when used within the manufacturer’s instructions for use; • Fetal distress, fetal death, or any congenital abnormality or birth defects. 8.2.5. Hospitalization Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility, or any prolongation of an existing admission. Admission also includes transfer within the hospital to an acute/intensive care unit (eg, from the psychiatric wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a tuberculosis unit). An emergency room visit does not necessarily constitute a hospitalization; however, the event leading to the emergency room visit is assessed for medical importance. Hospitalization does not include the following: • Rehabilitation facilities; • Hospice facilities; • Respite care (eg, caregiver relief); • Skilled nursing facilities; • Nursing homes; • Same-day surgeries (as outpatient/same-day/ambulatory procedures). Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical AE is not in itself an SAE. Examples include: • Admission for treatment of a preexisting condition not associated with the development of a new AE or with a worsening of the preexisting condition (eg, for workup of a persistent pretreatment laboratory abnormality); • Social admission (eg, subject has no place to sleep); • Administrative admission (eg, for yearly physical examination); • Protocol-specified admission during a study (eg, for a procedure required by the study protocol); • Optional admission not associated with a precipitating clinical AE (eg, for elective cosmetic surgery); • Hospitalization for observation without a medical AE; • Preplanned treatments or surgical procedures. These should be noted in the baseline documentation for the entire protocol and/or for the individual subject. Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery, should not be reported as SAEs. However, the medical condition for which the procedure was performed should be reported if it meets the definition of an SAE. For example, an acute appendicitis that begins during the reporting period should be reported if the SAE requirements are met, and the resulting appendectomy should be recorded as treatment of the AE. 8.3. Severity Assessment Note the distinction between the severity and the seriousness of an AE. A severe event is not necessarily an SAE. For example, a headache may be severe (interferes significantly with the subject's usual function) but would not be classified as serious unless it met one of the criteria for SAEs, listed above. 8.4. Special Situations 8.4.1. Protocol-Specified Serious Adverse Events Thromboembolic or ischemic events are considered important medical events. As important medical events, Pfizer is to be notified within 24 hours of awareness of any thromboembolic or ischemic event. Data entry and additional reporting requirements will follow the same instructions for all other SAEs as listed in Section 8.1. 8.4.2. Potential Cases of Drug-Induced Liver Injury Humans exposed to a drug who show no sign of liver injury (as determined by elevations in transaminases) are termed “tolerators,” while those who show transient liver injury, but adapt are termed “adaptors.” In some subjects, transaminase elevations are a harbinger of a more serious potential outcome. These subjects fail to adapt and therefore are "susceptible" to progressive and serious liver injury, commonly referred to as drug-induced liver injury (DILI). Subjects who experience a transaminase elevation above 3 times the upper limit of normal (× ULN) should be monitored more frequently to determine if they are an “adaptor” or are “susceptible.” In the majority of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 × ULN) by several days or weeks. The increase in TBili typically occurs while AST/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and TBili values will be elevated within the same lab sample). In rare instances, by the time TBili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded. The threshold of laboratory abnormalities for a potential DILI case depends on the subject’s individual baseline values and underlying conditions. Subjects who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values: • Subjects with AST/ALT and TBili baseline values within the normal range who subsequently present with AST OR ALT values >3 × ULN AND a TBili value >2 × ULN with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not available; • For subjects with baseline AST OR ALT OR TBili values above the ULN, the following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline: • Preexisting AST or ALT baseline values above the normal range: AST or ALT values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is smaller). • Preexisting values of TBili above the normal range: TBili level increased from baseline value by an amount of at least 1 × ULN or if the value reaches >3 × ULN (whichever is smaller). Rises in AST/ALT and TBili separated by more than a few weeks should be assessed individually based on clinical judgment; any case where uncertainty remains as to whether it The subject should return to the investigator site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should include laboratory tests, detailed history, and physical assessment. In addition to repeating measurements of AST and ALT and TBili, laboratory tests should include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma-glutamyl transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology. A detailed history, including relevant information, such as review of ethanol, acetaminophen (either by itself or as a coformulated product in prescription or over-the-counter medications), recreational drug, supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary tract) may be warranted. All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and TBili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason for the liver function test (LFT) abnormalities has yet been found. Such potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities. A potential DILI (Hy’s law) case becomes a confirmed case only after all results of reasonable investigations have been received and have excluded an alternative etiology. 8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and Occupational Exposure Exposure to the investigational product under study during pregnancy or breastfeeding and occupational exposure are reportable to Pfizer Safety within 24 hours of investigator awareness. 8.4.3.1. Exposure During Pregnancy For both unapproved/unlicensed products and for marketed products, an exposure during pregnancy (EDP) occurs if: • A female becomes, or is found to be, pregnant either while receiving or having been exposed (eg, because of treatment or environmental exposure) to the investigational product; or the female becomes or is found to be pregnant after discontinuing and/or being exposed to the investigational product: • An example of environmental exposure would be a case involving direct contact with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has been exposed to chemotherapeutic products). • A male has been exposed (eg, because of treatment or environmental exposure) to the investigational product prior to or around the time of conception and/or is exposed during his partner’s pregnancy. If a subject or subject’s partner becomes or is found to be pregnant during the subject’s treatment with the investigational product, the investigator must report this information to Pfizer Safety on the CT SAE Report Form and an EDP supplemental form, regardless of whether an SAE has occurred. In addition, the investigator must submit information regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject reports that she is pregnant and has been exposed to a cytotoxic product by inhalation or spillage) to Pfizer Safety using the EDP supplemental form. This must be done irrespective of whether an AE has occurred and within 24 hours of awareness of the exposure. The information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy). Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow-up to the initial EDP supplemental form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless pre-procedure test findings are conclusive for a congenital anomaly and the findings are reported). If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to Pfizer Safety as SAEs follows: • Spontaneous abortion includes miscarriage and missed abortion; • Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the investigational product. Additional information regarding the EDP may be requested by the sponsor. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the subject with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the subject was given the Pregnant Partner Release of Information Form to provide to his partner. 8.4.3.2. Exposure During Breastfeeding Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of an associated SAE, to Pfizer Safety within 24 hours of the investigator’s awareness, using the CT SAE Report Form. An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in accord with authorized use. However, if the infant experiences an SAE associated with such a drug’s administration, the SAE is reported together with the exposure during breastfeeding. 8.4.3.3. Occupational Exposure An occupational exposure occurs when, during the performance of job duties, a person (whether a healthcare professional or otherwise) gets in unplanned direct contact with the product, which may or may not lead to the occurrence of an AE. An occupational exposure is reported to Pfizer Safety within 24 hours of the investigator’s awareness, using the CT SAE Report Form, regardless of whether there is an associated SAE. Since the information does not pertain to a subject enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file. 8.4.4. Medication Errors Other exposures to the investigational product under study may occur in clinical trial settings, such as medication errors. 8.4.4.1. Medication Errors Medication errors may result from the administration or consumption of the investigational product by the wrong subject, or at the wrong time, or at the wrong dosage strength. Medication errors include: • Medication errors involving subject exposure to the investigational product; • Potential medication errors or uses outside of what is foreseen in the protocol that do or do not involve the participating subject. Such medication errors occurring to a study participant are to be captured on the medication error page of the CRF, which is a specific version of the AE page. In the event of a medication dosing error, the sponsor should be notified immediately. Whether or not the medication error is accompanied by an AE, as determined by the investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and non-serious, are recorded on an AE page of the CRF. Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report Form only when associated with an SAE. 8.5. Medical Device Complaint Reporting Requirements All medical device complaints, regardless of whether the medical device complaint is associated with an AE, will be recorded on the applicable pages within the CRF. This includes potential incidents or malfunctions associated with the use of a medical device product. An incident or malfunction is an event that might have led to death or serious deterioration in health, or if it occurred again might lead to death or serious deterioration in health. Pfizer is to be notified of all medical device complaints within 24 hours of the investigator’s awareness of the event. 9. DATA ANALYSIS/STATISTICAL METHODS Detailed methodology for summary and statistical analyses of the data collected in this study is outlined here and further detailed in a statistical analysis plan (SAP), which will be maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment. 9.1. Sample Size Determination No formal statistical hypothesis will be tested. The total sample size of approximately 36 subjects (24 subjects from B7841002 and 12 additional de novo subjects) is based on the number of subjects enrolled in study B7841002, and on clinical considerations to balance the need to minimize exposure of study subjects to the test article with the need to provide adequate safety and tolerability data for clinical development. 9. 2. 1. A n al y si s of t h e Effi c a c y E n d p oi nt A B R will b e c al c ul at e d a n d s u m m ari z e d d e s cri pti v el y. T h e A B R i s c al c ul at e d a s ( n u m b er of bl e e di n g e v e nt s/ o b s er v e d tr e at m e nt p eri o d i n d a y s) * 3 6 5. 2 5. C CI 9. 6. S af et y A n al y si s A d v er s e e v e nt s, E C G s, vit al si g n s ( bl o o d pr e s s ur e, p ul s e r at e, t e m p er at ur e a n d r e s pir at or y rat e), p h ys i c al e x a mi n ati o n s a n d s af ety l a b or at or y d at a (i n cl u di n g h e m at ol o g y , P T/I N R, a P T T, c h e mi str y , uri n aly si s, fi bri n o g e n, a nti -t hr o m bi n III a cti vit y a n d c ar di a c tr o p o ni n I) will b e r e vi e w e d a n d s u m m ari z e d o n a n o n g oi n g b a si s d uri n g t h e st u d y t o e v al u a t e t h e s af ety of s u bj e ct s. S af et y d at a will b e pr e s e nt e d i n t a b ul ar a n d/ or gr a p hi c al f or m at a n d s u m m ari z e d d e s cri pti v el y, w h er e a p pr o pri at e. I n ci d e n c e a n d s e v erit y of tr e at m e nt -e m er g e nt A E s ( T E A E s), wit h dr a w al s d u e t o T E A E s, a n d i nf u si o n a n d i nj e cti o n sit e r e a cti o n s will b e s u m m ari z e d b y d o s e l e v el. A b n or m al s af et y fi n di n g s will al s o b e pr e s e nt e d s e p ar at el y f or i n hi bit or s u bj e ct s b y d o s e l e v el. A b n or m al a n d cli ni c all y r el e v a nt c h a n g e s i n vit al si g n s a n d E C G p ar a m et er s will b e s u m m ari z e d b y d o s e l e v el a n d st u d y d a y. I n ci d e n c e a n d m a g nit u d e of a b n or m al l a b or at or y fi n di n g s will b e s u m m ari z e d b y d o s e l e v el. C CI c oll e ct e d d uri n g t h e c o ur s e of t h e st u d y will b e c a pt ur e d f or i n cl u si o n i nt o t h e st u d y d at a b a s e, u nl e s s ot h er wi s e n ot e d. A n y u nt o w ar d fi n di n g s i d e ntifi e d o n p h y si c al e x a mi n ati o n c o n d u ct e d aft er t h e a d mi ni str ati o n of t h e fir st d o s e of i n v e sti g ati o n al pr o d u ct will b e c a pt ur e d a s a n a d v er s e e v e nt, if t h o s e fi n di n g s m e et t h e d efi niti o n of a n a d v er s e e v e nt. 9. 7. I nt e ri m A n al y si s N o f or m al i nt eri m a n al ys i s will b e c o n d u ct e d f or t hi s st u d y. H o w e v er, a s t hi s i s a n o p e n -l a b el st u dy, t h e s p o n s or m a y c o n d u ct u n bli n d e d r e vi e w s of t h e d at a d uri n g t h e c o ur s e of t h e st u d y f or t h e p ur p o s e of s af ety a s s e s s m e nt, f a cilit ati n g d o s e -e s c al ati o n d e ci si o n s, C CI a n d/ or t o s u p p ort cli ni c al d e v el o p m e nt. 9. 8. D at a M o nit o ri n g C o m mitt e e T hi s st u d y will n ot u s e a d at a m o nit ori n g c o m mitt e e. 1 0. Q U A L I T Y C O N T R O L A N D Q U A L I T Y A S S U R A N C E Pfi z er or it s a g e nt will c o n d u ct p eri o di c m o nit ori n g vi sit s d ur i n g st u dy c o n d u ct t o e n s ur e t h at t h e pr ot o c ol a n d G o o d Cli ni c al Pr a cti c e s ( G C P s) ar e b ei n g f oll o w e d. T h e m o nit or s m a y r e vi e w s o ur c e d o c u m e nt s t o c o nfir m t h at t h e d at a r e c or d e d o n C R F s ar e a c c ur at e. T h e i n v e sti g at or a n d i n stit uti o n will all o w Pfi z er m o nitor s/ a u dit or s or it s a g e nt s a n d a p pr o pri at e r e g ul at or y a ut h oriti e s dir e ct a c c e s s t o s o ur c e d o c u m e nt s t o p erf or m t hi s v erifi c ati o n. T hi s v erifi c ati o n m a y al s o o c c ur aft er st u d y c o m pl eti o n. D uri n g st u d y c o n d u ct a n d/ or aft er st u d y c o m pl eti o n, t h e i n v e sti g at or sit e m a y b e s u bj e ct t o r e vi e w by t h e I RB/ E C, a n d/ or t o q u alit y a s s ur a n c e a u dit s p erf or m e d b y Pfi z er, or c o m p a ni e s w or ki n g wit h or o n b e h alf of Pfi z er, a n d/ or t o i n s p e cti o n b y a p pr o pri at e r e g ul at or y a ut h oriti e s. T h e i n v e sti g at or( s) will n otif y Pfi z er or its a g e nt s i m m e di at el y of a n y r e g ul at or y i n s p e cti o n n otifi c ati o n i n r el ati o n t o t h e st u d y . F urt h er m or e, t h e i n v e sti g at or will c o o p er at e wit h Pfi z er or it s a g e nt s t o pr e p ar e t h e i n v e sti g at or sit e f or t h e i n s p e cti o n a n d will all o w Pfi z er or it s a g e nt, w h e n e v e r f e a si bl e, t o b e pr e s e nt d uri n g t h e i n s p e cti o n. T h e i n v e sti g at or sit e a n d i n v e sti g at or will pr o m ptl y r e s ol v e a ny di s cr e p a n ci e s t h at ar e i d e ntifi e d b et w e e n t h e st u d y d at a a n d t h e s u bj e ct' s m e di c al r e c or d s. T h e i n v e sti g at or will pr o m ptl y pr o vi d e c o pi e s of t h e i n s p e cti o n fi n di n g s t o Pfi z er or it s a g e nt. B ef or e r e s p o n s e s u b mi s si o n t o t h e r e g ul at or y a ut h oriti e s, t h e i n v e sti g at or will pr o vi d e Pfi z er or it s a g e nt s wit h a n o p p ort u nit y t o r e vi e w a n d c o m m e nt o n r e s p o n s e s t o a n y s u c h fi n di n g s. It i s i m p ort a nt t h at t h e i n v e sti g at or( s) a n d t h eir r el e v a nt p er s o n n el ar e a v ail a bl e d uri n g t h e m o nit ori n g vi sit s a n d p o s si bl e a u dit s or i n s p e cti o n s a n d t h at s uffi ci e nt ti m e i s d e v ot e d t o t h e pr o c e s s. 11. DATA HANDLING AND RECORD KEEPING 11.1. Case Report Forms/Electronic Data Record As used in this protocol, the term CRF should be understood to refer to either a paper form or an electronic data record or both, depending on the data collection method used in this study. A CRF is required and should be completed for each included subject. The completed original CRFs are the sole property of Pfizer and should not be made available in any form to third parties, except for authorized representatives of Pfizer or appropriate regulatory authorities, without written permission from Pfizer. The investigator has ultimate responsibility for the collection and reporting of all clinical, safety, and laboratory data entered on the CRFs and any other data collection forms (source documents) and ensuring that they are accurate, authentic/original, attributable, complete, consistent, legible, timely (contemporaneous), enduring, and available when required. The CRFs must be signed by the investigator or by an authorized staff member to attest that the data contained on the CRFs are true. Any corrections to entries made in the CRFs or source documents must be dated, initialed, and explained (if necessary) and should not obscure the original entry. In most cases, the source documents are the hospital or the physician subject chart. In these cases, data collected on the CRFs must match the data in those charts. In some cases, the CRF may also serve as the source document. In these cases, a document should be available at the investigator site and at Pfizer that clearly identifies those data that will be recorded on the CRF, and for which the CRF will stand as the source document. 11.2. Record Retention To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, the investigator agrees to keep records, including the identity of all participating subjects (sufficient information to link records, eg, CRFs and hospital records), all original signed informed consent/assent documents, copies of all CRFs, safety reporting forms, source documents, and detailed records of treatment disposition, and adequate documentation of relevant correspondence (eg, letters, meeting minutes, and telephone call reports). The records should be retained by the investigator according to the ICH guidelines, according to local regulations, or as specified in the clinical study agreement (CSA), whichever is longer. If the investigator becomes unable for any reason to continue to retain study records for the required period (eg, retirement, relocation), Pfizer should be prospectively notified. The study records must be transferred to a designee acceptable to Pfizer, such as another investigator, another institution, or an independent third party arranged by Pfizer. Investigator records must be kept for a minimum of 15 years after completion or discontinuation of the study or for longer if required by applicable local regulations. The investigator must obtain Pfizer's written permission before disposing of any records, even if retention requirements have been met. 12. ETHICS 12.1. Institutional Review Board/Ethics Committee It is the responsibility of the investigator to have prospective approval of the study protocol, protocol amendments, informed consent/assent documents, and other relevant documents, eg, recruitment advertisements, if applicable, from the IRB/EC. All correspondence with the IRB/EC should be retained in the investigator file. Copies of IRB/EC approvals should be forwarded to Pfizer. The only circumstance in which an amendment may be initiated prior to IRB/EC approval is where the change is necessary to eliminate apparent immediate hazards to the subjects. In that event, the investigator must notify the IRB/EC and Pfizer in writing immediately after the implementation. 12.2. Ethical Conduct of the Study The study will be conducted in accordance with the protocol, legal and regulatory requirements, and the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), ICH Guideline for Good Clinical Practice, and the Declaration of Helsinki. 12.3. Subject Information and Consent All parties will ensure protection of subject personal data and will not include subject names or other identifiable data in any reports, publications, or other disclosures, except where required by law. When study data are compiled for transfer to Pfizer and other authorized parties, subject names, addresses, and other identifiable data will be replaced by numerical codes based on a numbering system provided by Pfizer in order to de-identify study subjects. The investigator site will maintain a confidential list of subjects who participated in the study, linking each subject’s numerical code to his or her actual identity. In case of data transfer, Pfizer will maintain high standards of confidentiality and protection of subjects’ personal data consistent with applicable privacy laws. The informed consent/assent documents and any subject recruitment materials must be in compliance with ICH GCP, local regulatory requirements, and legal requirements, including applicable privacy laws. The informed consent/assent documents used during the informed consent process and any subject recruitment materials must be reviewed and approved by Pfizer, approved by the IRB/EC before use, and available for inspection. The investigator must ensure that each study subject, or his or her legally acceptable representative, or parent(s) or legal guardian if a minor, is fully informed about the nature and objectives of the study and possible risks associated with participation. Whenever consent is obtained from a subject’s legally acceptable representative/parent(s) or legal guardian, the subject’s assent (affirmative agreement) must subsequently be obtained when the subject has the capacity to provide assent, as determined by the IRB/EC. If the investigator determines that a subject’s decisional capacity is so limited he/she cannot reasonably be consulted, then, as permitted by the IRB/EC and consistent with local regulatory and legal requirements, the subject’s assent may be waived with source documentation of the reason assent was not obtained. If the study subject does not provide his or her own consent, the source documents must record why the subject did not provide consent (eg, minor, decisionally impaired adult), how the investigator determined that the person signing the consent was the subject’s legally acceptable representative, the consent signer’s relationship to the study subject (eg, parent, spouse), and that the subject’s assent was obtained or waived. If assent is obtained verbally, it must be documented in the source documents. If the study includes minor subjects who reach the age of majority during the study, as recognized under local law, they must re-consent as adults to remain in the study. If the enrollment of emancipated minors is permitted by the study age criteria, the IRB/EC, and local law, they must provide documentation of legal status to give consent without the permission of a parent or legal guardian. The investigator, or a person designated by the investigator, will obtain written informed consent from each subject or the subject's legally acceptable representative, parent(s) or legal guardian and the subject’s assent, when applicable, before any study-specific activity is performed, unless a waiver of informed consent has been granted by an IRB/EC. The investigator will retain the original of each subject's signed consent/assent document. Where required, provisions for post-trial investigational product availability will be made in accordance with local CA/EC rules and regulations. 12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable regulatory authority in any area of the world, or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the investigational product, Pfizer should be informed immediately. In addition, the investigator will inform Pfizer immediately of any urgent safety measures taken by the investigator to protect the study subjects against any immediate hazard, and of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of. 13. DEFINITION OF END OF TRIAL 13.1. End of Trial in a Member State End of trial in a Member State of the European Union is defined as the time at which it is deemed that a sufficient number of subjects have been recruited and completed the study as stated in the regulatory application (ie, clinical trial application [CTA]) and ethics application in the Member State. Poor recruitment (recruiting less than the anticipated number in the CTA) by a Member State is not a reason for premature termination but is considered a normal conclusion to the study in that Member State. 13.2. End of Trial in All Other Participating Countries End of trial in all other participating countries is defined as last subject last visit (LSLV). 14. SPONSOR DISCONTINUATION CRITERIA Premature termination of this study may occur because of a regulatory authority decision, change in opinion of the IRB/EC, or investigational product safety problems, or at the discretion of Pfizer. In addition, Pfizer retains the right to discontinue development of PF-06741086 at any time. If a study is prematurely terminated, Pfizer will promptly notify the investigator. After notification, the investigator must contact all participating subjects and the hospital pharmacy (if applicable) within 7 days. As directed by Pfizer, all study materials must be collected and all CRFs completed to the greatest extent possible. 15. PUBLICATION OF STUDY RESULTS 15.1. Communication of Results by Pfizer Pfizer fulfills its commitment to publicly disclose clinical trial results through posting the results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with applicable local laws/regulations. In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted. www.clinicaltrials.gov Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer-sponsored interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a Pfizer product, regardless of the geographical location in which the study is conducted. US Basic Results are submitted for posting within 1 year of the primary completion date (PCD) for studies in adult populations or within 6 months of the PCD for studies in pediatric populations. PCD is defined as the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical study concluded according to the pre-specified protocol or was terminated. EudraCT Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer-sponsored interventional studies that are in scope of EU requirements. EU Basic Results are submitted for posting within 1 year of the PCD for studies in adult populations or within 6 months of the PCD for studies in pediatric populations. www.pfizer.com Pfizer posts Public Disclosure Synopses (clinical study report synopses in which any data that could be used to identify individual patients has been removed) on www.pfizer.com for Pfizer-sponsored interventional studies at the same time the US Basic Results document is posted to www.clinicaltrials.gov. 15.2. Publications by Investigators Pfizer supports the exercise of academic freedom and has no objection to publication by the principal investigator (PI) of the results of the study based on information collected or generated by the PI, whether or not the results are favorable to the Pfizer product. However, to ensure against inadvertent disclosure of confidential information or unprotected inventions, the investigator will provide Pfizer an opportunity to review any proposed publication or other type of disclosure of the results of the study (collectively, “publication”) before it is submitted or otherwise disclosed. The investigator will provide any publication to Pfizer at least 30 days before it is submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, the investigator agrees to delay the disclosure for a period not to exceed an additional 60 days. The investigator will, on request, remove any previously undisclosed confidential information before disclosure, except for any study- or Pfizer product-related information necessary to the appropriate scientific presentation or understanding of the study results. If the study is part of a multicenter study, the investigator agrees that the first publication is to be a joint publication covering all investigator sites, and that any subsequent publications by the PI will reference that primary publication. However, if a joint manuscript has not been submitted for publication within 12 months of completion or termination of the study at all participating sites, the investigator is free to publish separately, subject to the other requirements of this section. For all publications relating to the study, the institution will comply with recognized ethical standards concerning publications and authorship, including Section II - “Ethical Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, established by the International Committee of Medical Journal Editors. Publication of study results is also provided for in the CSA between Pfizer and the institution. In this section entitled Publications by Investigators, the defined terms shall have the meanings given to them in the CSA. If there is any conflict between the CSA and any attachments to it, the terms of the CSA control. If there is any conflict between this protocol and the CSA, this protocol will control as to any issue regarding treatment of study subjects, and the CSA will control as to all other issues. 16. REFERENCES 1. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447-56. 2. Astermark J. Overview of inhibitors. Semin Hematol. 2006; 43(suppl 4): S3-S7. 3. Maroney SA, Ellery PE, Wood JP, Ferrel JP, et al. Comparison of the inhibitory activity of human TFPIα and TFPIβ. Thromb Haemost 2013; 11:911-918. 4. Knappe S, Gorczyca ME, Jilma B, et al. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood. Thromb Haemost. 2013; 109:450-7. 5. Dahm A, Vlieg AVH, Bendz B et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood. 2003;101:4387-4392. T hi s f oll o wi n g i s a li st of a b br e vi ati o n s t h at m a y b e u s e d i n t h e pr ot o c ol. A b b r e vi ati o n T e r m A B R a n n u ali z e d bl e e di n g r at e C CI A D C C a nti b o d y -d e p e n d e nt c ell -m e di at e d c y t ot o xi cit y A E a d v er s e e v e nt A L B al b u mi n A L T al a ni n e a mi n otr a n sf er a s e A P C C a cti v at e d pr ot hr o m bi n c o m pl e x c o n c e ntr at e A P T T a cti v at e d p arti al t hr o m b o pl a sti n ti m e A S T a s p art at e a mi n otr a n sf er a s e A U C ar e a u n d er t h e c ur v e C CI BI D bi s i n di e ( “t wi c e a d a y ’) B MI b o d y m a s s i n d e x B P bl o o d pr e s s ur e C D 4 C D 4 c o u nt a b s ol ut e C D C c o m pl e m e nt d e p e n d e nt c y t ot o xi cit y C K cr e ati n e ki n a s e C m a x m a xi m u m c o n c e ntr ati o n C N S c e ntr al n er v o u s s ys t e m C R F c a s e r e p ort f or m C S A cli ni c al st u d y a gr e e m e nt C S F c er e br o s pi n al fl ui d C S R cli ni c al st u d y r e p ort C T A cli ni c al tri al a p pli c ati o n C V c ar di o v a s c ul ar DI LI dr u g -i n d u c e d li v er i nj ur y D M C d at a m o nit ori n g c o m mitt e e D N A d e o x yri b o n u cl ei c a ci d d P T dil ut e Pr ot hr o m bi n Ti m e D U di s p e n s a bl e u nit E C et hi c s c o m mitt e e E C G el e ctr o c ar di o gr a m E- D M C e xt er n al d at a m o nit ori n g c o m mitt e e E D P e x p o s ur e d uri n g pr e g n a n c y E H L e xt e n d e d h alf -lif e E U E ur o p e a n U ni o n E u dr a C T E ur o p e a n Cli ni c al Tri al s D at a b a s e F c R F c (fr a g m e nt cr y st alli z a bl e) r e c e pt or F EI B A A nti- i n hi bit or C o a g ul a nt C o m pl e x ( pr o pri et ary n a m e)] FI B fi bri n o g e n FI H fir st-i n-h u m a n F S H f olli cl e-sti m ul ati n g h or m o n e F VII a a cti v at e d c o a g ul ati o n f a ct or VII F VIII f a ct or VIII FI X f a ct or I X F X a f a ct or X a G C P G o o d Cli ni c al Pr a cti c e G G T G a m m a -gl ut a m yl tr a n sf er a s e G L O B gl o b uli n G L P G o o d L a b or at or y Pr a cti c e G M P G o o d M a n uf a ct uri n g Pr a cti c e H B c A b h e p atiti s B c or e a nti b o d y H B s A g h e p atiti s B s urf a c e a nti g e n H C V A b h e p atiti s C vir u s a nti b o d y HI V h u m a n i m m u n o d efi ci e n c y vir u s H R Q L h e alt h -r el at e d q u alit y of lif e I C H I nt er n ati o n al C o nf er e n c e o n H ar m o ni s ati o n I D i d e ntifi c ati o n I g G i m m u n o gl o b uli n G I ND i n v e sti g ati o n al n e w dr u g a p pli c ati o n I N R i nt er n ati o n al n or m ali z e d r ati o I P i n v e sti g ati o n al pr o d u ct I P M i n v e sti g ati o n al pr o d u ct m a n u al I RB i n stit uti o n al r e vi e w b o ar d I R C i nt er n al r e vi e w c o mmitt e e I R T i nt er a cti v e r e s p o n s e t e c h n ol o g y I UD i ntr a ut eri n e d e vi c e I V i ntr a v e n o u s I VI G i ntr a v e n o u s i m m u n o gl o b uli n I W R i nt er a cti v e w e b r e s p o n s e K E D T A di p ot a s si u m et h y l e n e di a mi n et etr a a c eti c a ci d 2 L F T li v er f u n cti o n t e st L L N l o w er li mit of n or m al L S L V l a st s u bj e ct l a st vi sit M A D m ulti pl e a s c e n di n g d o s e N/ A n ot a p pli c a bl e C CI N O A E L n o o b s er v e d a d v er s e eff e ct li mit P C D pri m ar y c o m pl eti o n d at e P D P h ar m a c o d y n a mi c s( s) P F S pr efill e d s yri n g e C CI C CI P E p h y si c al e x a m PI pri n ci p al i n v e sti g at or P K p h ar m a c o ki n eti c P T pr ot hr o m bi n ti m e Q M q u a q u e m o nt hl y ( “ o n c e m o nt hl y”) Q W q u a q u e w e e kl y ( “ o n c e w e e kl y ”) R N A ri b o n u cl ei c a ci d S A D si n gl e a s c e n di n g d o s e S A E s eri o u s a d v er s e e v e nt S A P st ati sti c al a n al ysi s pl a n S C s u b c ut a n e o u s S O P st a n d ar d o p er ati n g pr o c e d ur e S P R s urf a c e pl a s m o n r e s o n a n c e S R S D si n gl e r ef er e n c e s af et y d o c u m e nt S U S A R s u s p e ct e d u n e x p e ct e d s eri o u s a d v er s e r e a cti o n T bili t ot al bilir u bi n T E G t hr o m b o el a st o gr a p hy T F PI ti s s u e f a ct or p at h w a y i n hi bit or T G A t hr o m bi n g e n er ati o n a s s a y T N F t u m or n e cr o si s f a ct or U L N u p p er li mit of n or m al U S U nit e d St at e s Appendix 2. Thrombotic Adverse Events for Stopping Criteria 